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ABSTRACT
Introduction: Medullary thyroid carcinoma (MTC) originates in the thyroid parafollicular cells 
and represents 3-4% of the malignant neoplasms that affect this gland. Approximately 25% 
of these cases are hereditary due to activating mutations in the REarranged during Transfec-
tion (RET) proto-oncogene. The course of MTC is indolent, and survival rates depend on the 
tumor stage at diagnosis. The present article describes clinical evidence-based guidelines for 
the diagnosis, treatment, and follow-up of MTC. Objective: The aim of the consensus described 
herein, which was elaborated by Brazilian experts and sponsored by the Thyroid Department 
of the Brazilian Society of Endocrinology and Metabolism, was to discuss the diagnosis, treat-
ment, and follow-up of individuals with MTC in accordance with the latest evidence reported in 
the literature. Materials and methods: After clinical questions were elaborated, the available 
literature was initially surveyed for evidence in the MedLine-PubMed database, followed by the 
Embase and Scientific Electronic Library Online/Latin American and Caribbean Health Science 
Literature (SciELO/Lilacs) databases. The strength of evidence was assessed according to the 
Oxford classification of evidence levels, which is based on study design, and the best evidence 
available for each question was selected. Results: Eleven questions corresponded to MTC diag-
nosis, 8 corresponded to its surgical treatment, and 13 corresponded to follow-up, for a total of 
32 recommendations. The present article discusses the clinical and molecular diagnosis, initial 
surgical treatment, and postoperative management of MTC, as well as the therapeutic options 
for metastatic disease. Conclusions: MTC should be suspected in individuals who present with 
thyroid nodules and family histories of MTC, associations with pheochromocytoma and hy-
perparathyroidism, and/or typical phenotypic characteristics such as ganglioneuromatosis and 
Marfanoid habitus. Fine-needle nodule aspiration, serum calcitonin measurements, and ana-
tomical-pathological examinations are useful for diagnostic confirmation. Surgery represents 
the only curative therapeutic strategy. The therapeutic options for metastatic disease remain 
limited and are restricted to disease control. Judicious postoperative assessments that focus on 
the identification of residual or recurrent disease are of paramount importance when defining 
the follow-up and later therapeutic management strategies. Arq Bras Endocrinol Metab. 2014;58(7):667-700
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RESUMO
Introdução: O carcinoma medular de tireoide (CMT) origina-se das células parafoliculares da ti-
reoide e corresponde a 3-4% das neoplasias malignas da glândula. Aproximadamente 25% dos 
casos de CMT são hereditários e decorrentes de mutações ativadoras no proto-oncogene RET 
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Diagnosis, treatment, and follow-up of medullary thyroid carcinoma
(REarranged during Transfection). O CMT é uma neoplasia de curso indolente, com taxas de 
sobrevida dependentes do estádio tumoral ao diagnóstico. Este artigo descreve diretrizes base-
adas em evidências clínicas para o diagnóstico, tratamento e seguimento do CMT. Objetivo: O 
presente consenso, elaborado por especialistas brasileiros e patrocinado pelo Departamento de 
Tireoide da Sociedade Brasileira de Endocrinologia e Metabologia, visa abordar o diagnóstico, 
tratamento e seguimento dos pacientes com CMT, de acordo com as evidências mais recentes 
da literatura. Materiais e métodos: Após estruturação das questões clínicas, foi realizada busca 
das evidências disponíveis na literatura, inicialmente na base de dados do MedLine-PubMed 
e posteriormente nas bases Embase e SciELO – Lilacs. A força das evidências, avaliada pelo 
sistema de classificação de Oxford, foi estabelecida a partir do desenho de estudo utilizado, 
considerando-se a melhor evidência disponível para cada questão. Resultados: Foram defini-
das 11 questões sobre o diagnóstico, 8 sobre o tratamento cirúrgico e 13 questões abordando 
o seguimento do CMT, totalizando 32 recomendações. Como um todo, o artigo aborda o diag-
nóstico clínico e molecular, o tratamento cirúrgico inicial, o manejo pós-operatório e as opções 
terapêuticas para a doença metastática. Conclusões: O diagnóstico de CMT deve ser suspeitado 
na presença de nódulo tireoidiano e história familiar de CMT e/ou associação com feocromoci-
toma, hiperparatireoidismo e/ou fenótipo sindrômico característico, como ganglioneuromatose 
e habitus marfanoides. A punção aspirativa por agulha fina do nódulo, a dosagem de calcito-
nina sérica e o exame anatomopatológico podem contribuir na confirmação do diagnóstico. A 
cirurgia é o único tratamento que oferece a possibilidade de cura. As opções de tratamento da 
doença metastática ainda são limitadas e restritas ao controle da doença. Uma avaliação pós-
-cirúrgica criteriosa para a identificação de doença residual ou recorrente é fundamental para 
definir o seguimento e a conduta terapêutica subsequente. Arq Bras Endocrinol Metab. 2014;58(7):667-700
Descritores
Carcinoma medular de tireoide; NEM 2A; NEM 2B; proto-oncogene RET; diagnóstico; tratamento; seguimento
INTRODUCTION
M edullary thyroid carcinoma (MTC) originates in the thyroid parafollicular or C cells and re-
presents 3-4% of the malignant neoplasms that affect 
this gland (1) (A). Overall, 10,590 new cases of thyroid 
cancer were estimated among Brazilian women in 2012 
(National Cancer Institute/Instituto Nacional do Cân-
cer [Inca]; www.inca.gov.br/estimativa/2012). As-
suming that the percentage of MTC is similar to that 
reported in other countries, about 430 new cases of 
MTC would be diagnosed each year. 
MTC can be sporadic or hereditary (20-25%). The 
familial form is part of a genetic syndrome known as 
multiple endocrine neoplasia type 2 (MEN 2). The 
most common form of this syndrome is MEN 2A, 
which is characterized by MTC (95%), pheochromo-
cytoma (50%), and hyperparathyroidism (20%), while 
MEN 2B includes MTC (90%), pheochromocytoma 
(45%), ganglioneuromatosis (100%), Marfanoid habi-
tus (65%), and eye abnormalities (e.g., thickened cor-
neal nerves, conjunctivitis sicca, and an inability to 
cry tears). Familial MTC (FMTC) is defined by the 
 presence of MTC alone, and its diagnosis is based on 
the absence of pheochromocytoma or hyperparathy-
roidism in 2 or more family generations or the pre-
sence of mutations classically associated with FMTC 
(2,3) (D). Activating mutations in the REarranged 
during Transfection (RET) proto-oncogene are the 
cause of the hereditary disease form, and therefore 
molecular diagnosis is of paramount importance in 
MTC management (4) (A). Approximately 50% of 
sporadic MTC cases exhibit somatic mutations in the 
RET gene (4,5) (A/B). 
Calcitonin is a specific biomarker with a high sen-
sitivity for MTC diagnosis. Neoplastic C cells also 
produce the carcinoembryonic antigen (CEA), which 
can be used as a prognostic marker during the follow-
up of individuals with MTC (6,7) (B). Sporadic MTC 
is an indolent and usually solitary tumor, whereas the 
hereditary form is usually multicentric. Diagnosis of 
the sporadic form is usually established late in life (ap-
proximately the fifth or sixth decade). Neck lymph 
node metastases are detected in approximately 50% 
of cases at the time of diagnosis, while distant metas-
tases occur in 20% of cases (8-11) (B). Early surgical 
intervention is the only curative therapeutic approach 
(11) (B). The 10-year survival rate of patients with 
diseases that only affect the thyroid is 95%, while that 
in individuals with distant metastases varies from 15-
40% (12) (B).
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The recommendations described below resulted 
from the efforts of the Thyroid Department of the 
Brazilian Society of Endocrinology and Metabolism 
to formulate evidence-based clinical guidelines for the 
care of individuals with MTC. Our main goal is to as-
sist clinicians with the selection of the best strategies for 
patient management according to the characteristics of 
the Brazilian health system.
MATERIALS AND METHODS
The present consensus complies with the strategic po-
licy of the Thyroid Department of the Brazilian Soci-
ety of Endocrinology and Metabolism for the develop-
ment of national consensuses for the main diseases of 
the thyroid gland that are specifically formulated for 
the Brazilian population, while considering the actual 
situation of the national health system. The Program 
Guidelines, which were elaborated by the Brazilian 
Medical Association (Associação Médica Brasileira 
[AMB]) and the Federal Council of Medicine (Con-
selho Federal de Medicina [CFM]), served as a model 
for the present recommendations. The authors were 
selected according to their academic and scientific ac-
tivities and clinical experiences with the management 
of these diseases. The clinical questions most relevant 
to the clinical practice were then formulated. A search 
for relevant articles was performed in the databases 
MedLine-PubMed, Embase, and Scientific Electronic 
Library Online/Latin American and Caribbean Health 
Science Literature (SciELO-Lilacs). The grade of re-
commendation or strength of evidence (Table 1) of the 
studies was established according to the Oxford clas-
sification (13) (D), which is based on the study design 
used, while considering the best available evidence and 
the Brazilian experience. This method was also used 
in the AMB/CFM Program Guidelines, to which the 
Brazilian medical community and academic milieu 
grew accustomed. 
The search of the MedLine-PubMed, Embase, and 
SciELO databases allowed the identification of studies 
that focused on several features related to the diagnosis, 
treatment, and follow-up of MTC. The recommenda-
tions presented herein summarize the relevant aspects 
of each clinical question and are categorized as a func-
tion of the evidential strength on which they are based, 
as described in table 1. 
PART I: MTC: DIAgNOSIS
1. When should we suspect MTC?
The most common clinical presentation of MTC is the 
appearance of a single thyroid nodule. Thyroid nodu-
les might also eventually appear within the context of 
a multinodular goiter or might represent an incidental 
finding in imaging exams of the neck (14) (D). Neck 
lymph node enlargement is present in 50% of these ca-
ses (8,9) (B). Although the detection of fast-growing 
or hardened lymph nodes or their fixation to adjacent 
structures is suggestive of malignancy, this does not 
specifically indicate MTC. The presence of associated 
endocrine neoplasms (pheochromocytoma, hyperpara-
thyroidism), cutaneous lichen amyloidosis on the in-
terscapular region, ganglioneuromas, typical facies, or 
a history of thyroid cancer and/or of RET mutations 
in first-degree relatives might be suggestive of heredi-
tary MTC (2-4,15) (D/D/B/C). In a small fraction 
of patients, MTC exhibits systemic manifestations such 
as diarrhea, flushing, Cushing’s syndrome due to the 
ectopic secretion of adrenocorticotropic hormone 
(ACTH), or fractures secondary to bone metastases 
(2,3,15) (D/D/C).
There are no specific clinical findings that permit 
a firm diagnosis of MTC. For this reason, if CMT is 
suspected, the physician should order diagnostic tests, 
including fine-needle aspiration biopsy (FNAB) and se-
rum calcitonin measurements. 
Recommendation 1
A thyroid nodule is the most common clinical manifes-
tation of MTC. MTC must be specifically suspected in 
individuals with family history of thyroid cancer, RET 
mutations, and/or associations with pheochromocyto-
ma, hyperparathyroidism, cutaneous lichen amyloidosis 
and/or typical findings upon physical examination such 
Diagnosis, treatment, and follow-up of medullary thyroid carcinoma
Table 1. Definition of the grades of recommendation and strength of evidence 
according to the Oxford classification (adapted from reference 13) (D)
Recommendation Strength of evidence
A Experimental or observational studies with greater 
consistency
B Experimental or observational studies with lesser 
consistency
C Case reports (uncontrolled studies)
D Opinions without critical evaluations and those based on 
consensuses, physiological studies, or animal models
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as Marfanoid habitus and mucosal neuromas (Recom-
mendation B). 
2. What is the role of fine-needle aspiration biopsy 
(FNAB) in the diagnosis of MTC?
FNAB is among the most important tools for the diag-
nostic assessment of thyroid nodules. The characteristic 
cytological findings in MTC include the presence of 
predominantly isolated cells or cells arranged in isola-
ted cohesive groups, with a round-to-oval, polyhedral, 
or fusiform shape, and the predominance of 3-dimen-
sional arrangements; abundant or scarce cytoplasm 
that usually contains acidophil granulation; 2 or more 
typically round nuclei of variable size (usually present 
in alterations associated with endocrine disorders) and 
eccentric position; and the presence of amyloid, which 
usually appears as clumps of amorphous matter detec-
ted by Congo red staining. Further cytological findings 
include the presence of fusiform cells and cytoplasmic 
(comet-like) projections (16) (B). 
The sensitivity of FNAB for diagnosing MTC in a 
thyroid nodule varies from 46.1-63% (17-19) (B). Al-
though non-diagnostic, the FNAB findings in MTC are 
indicative of surgery in 99% of cases (17-19) (B). Ap-
proximately 82% of MTC cases are correctly identified 
by FNAB, while 9% are false-negative results (18,19) 
(B).
The most frequent reasons for FNAB failure are in-
adequate sampling and multinodular goiters (because 
the malignant nodule might not be selected for assess-
ment) (20) (B). Additionally, differential diagnosis be-
tween MTC and other malignant thyroid neoplasms 
(particularly follicular lesions, Bethesda category III or 
IV) might be difficult because the cytological findings 
can be similar (20,21) (B). 
The measurement of calcitonin in the washout fluid 
has been recommended to improve the diagnostic 
sensitivity of FNAB for MTC (22,23) (B/C). In a re-
cent retrospective study, the cytology detected MTC 
in 21/37 lesions with 56.8% sensitivity whereas the 
measurement of calcitonin in the washout fluid showed 
sensitivity and specificity rates of 100% using a cutoff of 
36 pg/mL (24) (B).
The failure to diagnose MTC in a cytological ex-
amination might negatively impact the therapeutic 
management of patients (20) (B). Immunochemical 
staining for calcitonin might be useful in doubtful cas-
es (25) (C). Other methods that might facilitate the 
diagnosis of MTC include scanning electron micros-
copy and assessments of calcitonin mRNA expression; 
however, these are not part of the diagnostic routine 
(25-28) (C).
Recommendation 2
FNAB should be included in assessments of thyroid no-
dules suspected of MTC (Recommendation B). Diag-
nosis might be facilitated by the use of additional te-
chniques such as calcitonin measurement in the FNAB 
washout fluid (Recommendation B) and immunocyto-
chemistry (Recommendation C).
3. What is the role of the serum calcitonin 
measurement in thyroid nodule assessments?
The indication for serum calcitonin measurements 
in thyroid nodule assessments remains controversial. 
According to the basal calcitonin levels, the positi-
ve predictive values of this test are 8.3%, 25%, and 
100% for calcitonin levels of 20-50 pg/mL, 50-100 
pg/mL, and > 100 pg/mL, respectively (29) (A). Ac-
cording to some authors, the basal calcitonin levels 
should be measured first, followed by a pentagastrin 
stimulation test if the basal calcitonin levels exceed 
10 pg/mL. The risk of MTC is greater than 50% if 
the pentagastrin-stimulated calcitonin values > 100 
pg/mL (30) (D). In comparison with the ultrasensi-
tive calcitonin, the pentagastrin test still shows better 
diagnostic capability (31) (A). However, the penta-
gastrin stimulation test is not available in Brazil. The 
calcium stimulation test can be used as an alternati-
ve (32) (B). Nevertheless, recent studies have shown 
that with the improved sensitivity of the new assays, 
both basal and stimulated calcitonin have similar ac-
curacy, which reduces the relevance of the stimulation 
tests in multiple conditions (33) (B). 
Calcitonin is a sensitive and specific biomarker 
for the diagnosis of C cell hyperplasia and/or MTC. 
Increased calcitonin levels might also be present in 
other diseases such as chronic kidney failure, hyper-
parathyroidism, neuroendocrine neoplasms, lung and 
prostate tumors and autoimmune thyroiditis (34,35) 
(D/B), which are considered classic causes of false-
positive results. Presence of heterophile antibodies 
(human antibodies with broad reactivity with anti-
bodies of other species) can also interfere in dosage, 
causing falsely elevated values (or, less frequently, 
false-positive results) (36) (B). Of note, recent study 
conducted in Brazil found no changes in the serum 
Diagnosis, treatment, and follow-up of medullary thyroid carcinoma
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calcitonin levels of individuals with Hashimoto’s thy-
roiditis (37) (B). False-negative results might be due 
to the hook effect and, less often, to non-calcitonin-
secreting MTC (38,39) (C). 
Compared with FNAB, the sensitivity of the calcito-
nin measurement for preoperative diagnosis of MTC is 
higher (approximately 100% sensitivity and 95% speci-
ficity) (18,40,41) (B). Individuals with MTC that was 
diagnosed from a calcitonin measurement during the 
investigation of thyroid nodules exhibit better postop-
erative outcomes than do those diagnosed by FNAB, 
with 10-year survival rates of 86.8% and 43.7%, respec-
tively (42) (B).
In North America, studies of cost-effectiveness ob-
tained results favorable to the inclusion of calcitonin 
measurements in initial thyroid nodule assessments 
(43,44) (D/B). Those data lend further support to 
the usefulness of calcitonin measurements in nodule 
investigations. Those results notwithstanding, the low 
prevalence of MTC (0.42-2.85%), the test costs, and 
problems with the standardization of the cutoff points 
cast doubts on the actual benefit provided by calcito-
nin measurements (42,45-47) (B). Additionally, the 
reproducibility of those results in our milieu is doubt-
ful. For those reasons, the Brazilian consensus for thy-
roid nodules does not recommend the measurement of 
serum calcitonin in the initial nodule assessment (14) 
(B). However, measurement of calcitonin in the FNAB 
washout fluid may be useful in nodules with undeter-
mined results (Bethesda category III/IV), considering 
the difficulties of FNAB to differentiate MTC from 
other thyroid malignancies (particularly follicular le-
sions) (24) (B).
The prevalence of MTC in individuals with multi-
nodular goiters varies from 0-3.1% (48) (A). It is worth 
bearing in mind that FNAB might yield false-negative 
results in cases of multinodular goiters because not all 
nodules can be feasibly assessed (49) (D). Additionally, 
small MTC foci might not be identified with thyroid 
ultrasound (US). For all those reasons, the serum calci-
tonin measurement might be useful for detecting MTC 
in cases of multinodular goiter (50,51) (A).
Recommendation 3
MTC screening via a serum calcitonin measurement 
in individuals with thyroid nodules remains contro-
versial. Because of problems with reference value stan-
dardization and its doubtful cost-effectiveness, the 
measurement of serum calcitonin is not indicated in 
the routine investigation of thyroid nodules (Recom-
mendation B).
4. What are the meanings of the serum levels of 
tumor markers for the initial diagnosis of MTC?
MTC secretes a variety of products, including calcito-
nin, CEA, amyloid, somatostatin, ACTH, vasoactive 
intestinal peptide (VIP), and serotonin, among others 
(52,53) (B). Calcitonin is the most important bioma-
rker and is used in the diagnosis, surgical planning, pos-
toperative management, and prognosis of individuals 
with MTC (54) (D).
In individuals with MTC, the preoperative calcito-
nin levels correlate with the tumor size and the presen ce 
of metastases (6,7) (B). Calcitonin levels < 100 pg/mL 
are associated with an average tumor diameter of 3 
mm, while levels > 1,000 pg/mL are associated with an 
average tumor diameter of 2.5 cm. Neck lymph node 
metastases might be present with basal calcitonin lev-
els of 10-40 pg/mL, while metastatic disease should 
be suspected at levels of 150-400 pg/mL. The presen-
ce of lymph node metastases or calcitonin levels > 400 
pg/mL indicate the need to identify distant metastases 
(6,7) (B).
Additionally, the serum CEA levels might be used 
for the risk stratification of individuals with MTC. CEA 
levels > 30 ng/mL are suggestive of lymph node metas-
tases in the ipsilateral central and lateral neck compart-
ments, while levels > 100 ng/mL correlate with contra-
lateral lymph node metastases and distant metastases. 
Values > 30 ng/mL were found to correlate with low 
cure rates (55) (B).
The preoperative serum calcitonin levels seem to cor-
relate more strongly with extensions of MTC, as com-
pared to the neck US findings. Basal calcitonin levels 
of 20, 50, 200, and 500 pg/mL exhibited correlations 
with metastases in the lymph nodes of the ipsilateral, 
lateral, and central compartments, contralateral central 
compartment, contralateral lateral compartment, and 
superior mediastinum, respectively (56) (B). 
Recommendation 4
Preoperative calcitonin levels correlate with the tumor 
size and stage and indicate the presence of local and/or 
distant metastases (Recommendation B). The indivi duals 
with suspected MTC and calcitonin levels > 150 ng/mL 
must be investigated for the presence of locoregional and 
distant metastases by imaging tests (please see Recom-
mendation 6, Flowchart 1) (Recommendation B).
Diagnosis, treatment, and follow-up of medullary thyroid carcinoma
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5. What is the value of neck US for the diagnosis of 
MTC?
Thyroid US is a relevant part of a thyroid nodule assess-
ment. US allows an accurate assessment of the nodule 
size and characteristics, as well as the identification of 
other nodules. Some nodule characteristics evidenced 
by US correlate with a higher risk of malignancy, in-
cluding hypoechogenicity, microcalcifications, irregular 
margins, predominantly central vascularization, and the 
presence of enlarged neck lymph nodes (57-59) (B).
Most individuals with MTC (> 90%) exhibit hy-
poechoic nodules, intranodular calcifications, and an 
absence of the halo sign on US; further possible findings 
include the presence of intranodular (79%) and peri-
nodular (50%) blood flow (60) (B). Some cases exhibit 
intranodular bright echogenic foci that correspond to 
amyloid-surrounded calcium deposits (61) (B). 
Neck US is the most sensitive imaging method for 
neck metastasis detection (10) (B). Approximately 75% 
of patients with MTC that is clinically detectable by 
palpation exhibit lymph node metastases (8) (B). As the 
presence of lymph node and/or distant metastases indi-
cates the need for changes in the therapeutic manage-
ment, US might be considered indispensable for treat-
ment planning. The sensitivity of preoperative neck 
US is considered as moderate, since 32% and 14% of 
individuals exhibit false-negative results in the central 
and ipsilateral areas, respectively (62) (B). However, a 
recent study described higher rates of sensitivity of US 
in predicting metastasis in the lateral and central neck 
(93.8% and 30.0%, respectively) (63) (B). One impor-
tant limitation of US is that it is operator-dependent, 
and therefore the results vary as a function of the opera-
tor’s experience. This most likely explains why a larger 
number of neck lymph node metastases are detected 
with surgical dissection, compared to US. Neverthe-
less, the sensitivity, specificity, and diagnostic accuracy 
of US for the preoperative detection of neck metastases 
are superior to those of computed tomography (CT; 
77, 70, and 74% vs. 62, 79, and 68%, respectively) (64) 
(B). Preoperative neck US is a valuable tool in assess-
ing patients with thyroid nodules; it provides useful 
information predicting cervical lymph node metastasis, 
especially in the in the lateral neck, and thus defining 
surgical extension (63) (B).
Recommendation 5
Neck US is indicated in all individuals with suspected 
MTC (Recommendation B). In addition to identifying 
characteristics suggestive of malignancy in the thyroid 
nodules and allowing the performance of US-guided 
FNAB, US is the most sensitive test for detecting neck 
metastases and thus contributes to therapeutic plan-
ning (Recommendation B). 
6. Which complementary tests should be performed 
before thyroidectomy in patients with suspected MTC?
The aim of the preoperative assessment of individuals with 
suspected or confirmed MTC is to establish the extension 
of thyroid disease and to identify the eventual presence 
of associated comorbidities such as hyperparathyroidism 
and/or pheochromocytoma in hereditary cases.
The presence of local and/or distant metastases in-
terferes with surgery planning in individuals with MTC. 
Neck metastases appear early during the course of MTC 
(9,65) (B). Distant metastases are detected in 7-17% of 
all cases at the time of diagnosis and frequently appear 
in multiple sites (lungs, liver, bones, and less often in 
the brain and skin) (10,11,66,67) (B/B/B/A).
Neck US must be performed in all affected indivi-
duals (56-58) (B). Findings suggestive of neck metasta-
ses or calcitonin levels > 400 pg/mL indicate the need 
Diagnosis, treatment, and follow-up of medullary thyroid carcinoma
Thyroid nodule
Suspicious FNAB*? 
Serum calcitonin measurement
MTC
RET molecular analysis 
Excluded MTC 
Evaluation/management 
for FNAB suspicious 
for malignancy
Excluded 
pheochromocytoma
Pheochromocytoma
Adrenal surgery
CEA, calcium and
24-urinary metanephrines
Calcitonin levels 
> 400 pg/mL
Evaluation of 
distant metastasis 
 
 Neck US 
Total thyroidectomy 
with or without 
neck dissection
* Findings suggestive of MTC: triangular or polygonal cells, cytoplasmic granules,
eccentric nuclei with coarsely granular chromatin and amyloid.
Flowchart 1. Initial diagnostic approach of medullary thyroid carcinoma.
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for additional tests (6,7) (B). It is worth noting that the 
radiological detection of distant metastases is quite im-
probable when the calcitonin levels are < 250 pg/mL 
(68) (B). The most efficacious approach to diagnosing 
distant metastases includes a combination of CT of the 
neck and chest and magnetic resonance imaging (MRI) 
of the liver (10) (B). The risk of distant metastases is 
similar in individuals with sporadic or hereditary MTC 
(7) (B).
Pheochromocytoma is a tumor that originates in 
the chromaffin cells of the adrenal medulla and oc-
curs in approximately 30-50% of individuals with 
MEN 2A or 2B. Adrenomedullary disease is more 
frequently bilateral (up to 78% of cases) in MEN 2, 
thus contrasting with sporadic pheochromocytoma, 
which usually appears as a single unilateral lesion. Ad-
ditionally, pheochromocytoma tends to appear earlier 
in individuals with MEN 2 and seldom metastasizes. 
The clinical manifestations of pheochromocytoma are 
caused by catecholamine hypersecretion and include 
the most frequent manifestations of arterial hyperten-
sion, tachycardia, headaches, and excessive sweating 
(69,70) B/C). Nevertheless, some individuals might 
merely exhibit a discrete increase in catecholamine le-
vels that is unattended by any signs or symptoms (71) 
(D). 
Individuals with hereditary MTC should be screened 
for pheochromocytoma, given their high risk of that 
disease (72) (B). As up to 10% of apparently sporadic 
MTC have a RET germline mutation, the presence of 
pheochromocytoma should be excluded in any patient 
with suspected MTC before the thyroidectomy, due 
to the high risk of anesthesia and the surgical proce-
dure (73,74)(D/B). A pheochromocytoma diagnosis is 
based on the identification of excessive catecholamine 
production by measuring the plasma and/or urine cat-
echolamine and/or metanephrine levels. The measure-
ment of plasma fractionated metanephrines seems to be 
the most useful test in cases of hereditary pheochromo-
cytoma, with sensitivity and specificity rates of 99% and 
98%, respectively. The sensitivity and specificity rates of 
urine metanephrines, plasma catecholamines, and urine 
catecholamines are 97-100% and 93-94%, 76-84% and 
81-88%, and 84-86% and 88-99%, respectively (75,76) 
(B). Therefore, normal fractionated plasma metaneph-
rines levels practically rule out pheochromocytoma in 
high-risk patients such as those with genetic syndromes 
(77-79) (B/B/D). When plasma fractionated meta-
nephrine measurements are unavailable, urine levels 
might be assessed.
Computed tomography or MRI of the abdomen 
might be performed to identify the localization of a 
pheochromocytoma. CT of the abdomen was able to 
identify the localization of hereditary adrenal tumors in 
76% of the evaluated cases (80) (B). Some CT-detect-
able nodule features might be helpful for the differential 
diagnosis among various types of adrenal lesions, includ-
ing adenoma, pheochromocytoma, and carcinoma. The 
lesion density is 1 of the parameters that helps to dis-
tinguish adrenal adenomas from non-adenomas because 
adenoma densities are low due to their high intracellular 
lipid contents. CT densities are measured in Hounsfield 
units (HU); with a cutoff point of 10 HU, non-contrast-
enhanced CT exhibits a 75% sensitivity rate and 100% 
specificity rate for the differentiation between adrenal 
adenomas and non-adenomas. Adenoma densities are 
usually lower than those of other tumors (pheochromo-
cytoma, carcinoma), and contrast washout occurs faster 
in adenomas, compared to other adrenal lesions. A > 
50% washout at 10 minutes after administration exhibits 
100% sensitivity and specificity for the identification of 
adrenal adenomas, compared to pheochromocytomas, 
carcinomas, and metastatic lesions (81-83) (B).
Hyperparathyroidism occurs in approximately 10-
20% of individuals with MEN 2A and is either asymp-
tomatic or presents with manifestations secondary to 
hypercalcemia (84) (D). In suspected cases of heredi-
tary MTC associated with MEN 2A, a serum albumin-
adjusted calcium measurement should be included in 
the preoperative investigation (73,85) (D).
Recommendation 6 (Flowchart 1)
Neck US must be performed in all affected individuals 
for detection of locoregional metastases. In individu-
als with suspected locoregional metastases or calcitonin 
levels > 400 pg/mL, the presence of distant metasta-
ses must be investigated before surgery (Recommenda-
tion B). The presence of pheochromocytoma must be 
investigated by the measurement of plasma fractiona-
ted metanephrines or urine metanephrine levels, if not 
available the blood measurement (Recommendation B). 
Once the diagnosis is confirmed, the adrenal tumor 
must be removed before thyroidectomy (Recommen-
dation B). The presence of hyperparathyroidism might 
be investigated through a serum calcium level measu-
rement after adjusting for the albumin concentration 
(Recommendation D).
Diagnosis, treatment, and follow-up of medullary thyroid carcinoma
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7. Which individuals with confirmed or suspected 
MTC should be subjected to RET proto-oncogene 
molecular testing?
The RET proto-oncogene comprises 21 exons and enco-
des a tyrosine-kinase receptor that is expressed in neural 
crest-derived cells, including the thyroid C cells, adrenal 
medulla, and parathyroid glands. The RET protein com-
prises 3 domains: an extracellular cysteine-rich domain 
with cadherin-like repeats, a transmembrane domain, and 
an intracellular domain with 2 tyrosine-kinase domains 
(TK1 and TK2). Hereditary MTC affects approximately 
1 in every 30,000 individuals and is caused by germli-
ne mutations in the RET proto-oncogene, an autosomal 
dominant genetic syndrome with approximately 100% 
penetrance and a variable phenotype. The mutations 
mainly affect the RET exons 10, 11, and 16, and less 
commonly the exons 5, 8, 13, 14, and 15 (84,86) (D). 
Several studies have found correlations between spe-
cific RET mutations and the various clinical syndromes 
associated with MEN 2. Mutations at codon 634 (exon 
11) are associated with the presence of pheochromocy-
toma and/or hyperparathyroidism, while mutations at 
codon 918 (exon 16) are specific for MEN 2B. Simi-
larly, mutations at codons 768 and 804 are associated 
with FMTC (Table 2) (87,88) (B/D).
Molecular diagnosis is superior to clinical and/or 
biochemical diagnosis for the identification of asymp-
tomatic individuals who are at risk of neoplasia (89-91) 
(B/C/B). Molecular testing allows the identification 
of the RET mutations that cause MEN 2A and MEN 
2B in 95–100% of the evaluated cases (92,93) (B/D).
Genetic screening should be performed in all indi-
viduals with MTC, rather than in the cases suspected 
of the hereditary form only, as 4-10% of apparently 
sporadic MTCs exhibit germline RET mutations; these 
occur particularly among young patients and/or those 
with multifocal disease (42,94-96) (B).
Therefore, investigations of RET proto-oncogene 
mutations are of paramount importance in the diag-
nostic assessment of and therapeutic planning for indi-
viduals with MTC.
Recommendation 7
A molecular assessment is indicated for all individuals 
with C cell hyperplasia, (familial or apparently sporadic) 
MTC, and/or MEN 2 (Recommendation B). The mo-
lecular diagnosis might guide the choice of therapeutic 
procedures and consequently change the natural course 
of disease, indicate genetic counseling, and help to esta-
blish the disease prognosis (Recommendation B).
Diagnosis, treatment, and follow-up of medullary thyroid carcinoma
Table 2. Correlations between the clinical presentations and germline RET mutations in hereditary medullary thyroid carcinoma
Phenotype Clinical presentation % RET germline mutationExon (Codons)
Sporadic MTC 75-80 None
Hereditary 20-25
MEN 2A MTC, pheochrocytoma, hyperparathyroidism 80-90 8 (G533)
10 (C609, C611, C618, C620)
11 (C630, C633, C634*, 635/insertion, S649)
13 (E768, L790, Y791)
14 (V804)
15 (S891)
16 (R912)
MEN 2B MTC, pheochrocytoma, marfanoid habitus 1-5 14 (V804+E805, V804+Y806, V804 e S904)
15 (A883)
16 (M918T*)
FMTC MTC 10-15 5 (R321)
8 (531/9 duplication, G533)
10 (C609, C611, C618, C620)
11 (C630, C633, C634, 635/insertion, S649)
13 (E768, L790, Y791)
14 (V804)
15 (Y891)
16 (R912)
MEN: multiple endocrine neoplasia; MTC: medullary thyroid carcinoma. * Most frequent mutations.
Co
py
rig
ht
©
 A
BE
&
M
 to
do
s o
s d
ire
ito
s r
es
er
va
do
s.
675Arq Bras Endocrinol Metab. 2014;58/7
8. When should the relatives of individuals with 
MTC be assessed? What is the relevance of a RET 
molecular assessment in such individuals?
Hereditary MTC is an autosomal dominant disease, 
and therefore the likelihood of transmission from 1 
generation to the next is 50% (89) (B). Following the 
identification of a RET mutation in an individual (pro-
band), all of his or her first-degree relatives should be 
subjected to genetic assessment. The molecular analy-
sis of the RET proto-oncogene in a proband’s relatives 
is of paramount importance because it allows for early 
diagnosis and treatment and consequently better prog-
nosis (87,93) (B). For these reasons, the indication of 
molecular testing is considered essential and is recom-
mended in the guidelines developed by the American 
Thyroid Association (ATA) and the European Thyroid 
Association (ETA), as well as in the Clinical Guidelines 
on Medullary Thyroid Carcinoma for Private Health 
Insurance and Plans from the Brazilian Medical Asso-
ciation and the National Regulatory Agency for Private 
Health Insurance and Plans (73, 97,98) (D). 
Total thyroidectomy should be considered in asymp-
tomatic carriers of RET mutations (73,89) (D/B). The 
appropriate age for prophylactic surgery depends on the 
results of RET molecular testing, the clinical data, and 
the serum calcitonin levels. The various  mutation types 
correlate with the degree of MTC aggressiveness, and 
therefore molecular testing facilitates decision-making 
with respect to the extent of surgery and the age at 
which surgery should performed. Additionally, the pre-
operative serum calcitonin levels contribute to surgery 
planning and the establishment of disease prognosis, 
in addition to being used in postoperative follow-ups 
(6,99,100) (B/C/B). The presence of neck metastases 
should be also investigated with physical examinations 
and US before surgery (60,62,100) (B).
Based on genotype-phenotype correlation studies, 
ATA formulated a series of recommendations for pro-
phylactic thyroidectomy in asymptomatic RET mutation 
carriers. The different types of mutations are classified in 
4 risk-based categories according to the tumor aggres-
siveness (A < B < C < D). In individuals with ATA A 
and B mutations (codons 768, 790, 791, 804 and 891 
and 609, 611, 618, 620, and 630, respectively), the risk 
of MTC is moderate, and in most cases, prophylactic 
surgery might be performed after the age of 5 years. In-
dividuals with mutations in codon 634 (ATA risk level 
C) are at risk of developing MTC early in life, and pro-
phylactic surgery should be performed before the age 
Diagnosis, treatment, and follow-up of medullary thyroid carcinoma
of 5 years (101) (B). Individuals with phenotype MEN 
2B-associated mutations (ATA risk level D) have an even 
higher risk of early MTC development and therefore 
should be subjected to prophylactic thyroidectomy prior 
to 1 year of age or at the time of diagnosis (73) (D). 
In children and young adults with RET mutations, 
the presence of a palpable thyroid nodule at the time 
of diagnosis correlates strongly with persistent or re-
current MTC (100) (B). Those data reinforce the re-
levance of the early investigation of RET mutations. 
Relatives who test negative for RET mutations are 
considered to have no risk of MTC and/or associated neo-
plasms and might thus be released from further follow-up. 
Recommendation 8
All first-degree relatives of individuals with MTC and 
germline RET mutations should be subjected to mole-
cular screening (Recommendation B). 
9. Does the mutation type interfere with the clinical 
presentation of MTC?
Most families with MEN 2A exhibit mutations in 1 
of the 5 cysteine residues in exon 10 (codons 609, 
611, 618, and 620) or 11 (codon 634) of the RET 
extracellular domain (Table 2). All mutations in codon 
634 are associated with pheochromocytoma and/or 
hyperparathyroidism (87,92) (B). Specific amino acid 
changes in the same codon interfere with the genotype-
-phenotype correlation. In individuals with MEN 2A, 
mutation C634R is associated with a higher rate of me-
tastasis at the time of diagnosis, compared to mutations 
C634W and C634Y (102) (B). 
The risk of pheochromocytoma in individuals with 
MEN 2 varies as a function of the mutated codon. The 
adrenal tumor occurrence rates are 28%, 21%, and 3% 
in carriers of mutations in the highest-risk category 
(mutations in codon 918), in the high-risk category 
(mutations in codons 634, 630, 609, 611, 618, and 
620), and in the lower-risk category (mutations in co-
dons 768, 790, 791, 804, and 891) (72) (B). Mutation 
C634W correlates strongly with a high penetrance of 
pheochromocytoma (103) (B). 
A specific mutation in codon 16 (M918T) has been 
found in approximately 95% of individuals with MEN 
2B, the mutation A883F (exon 15) has been identified 
in 2-3% of the cases, and the double mutation V804M/
Y806C (exon 14) in the same allele has been described in 
1 patient with MEN 2B. Mutations in codons 883 and 
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918 correlate with the occurrence of MTC at a younger 
age, an increased risk of metastasis, and an increased 
disease-specific mortality (86,92,104) (D/B/B). 
Approximately 90% of families with hereditary 
MTC exhibit mutations in RET exon 10 (codons 609, 
611, 618, and 620) and exon 11 (codon 634) (6,10) 
(B). Substitutions in the tyrosine-kinase domain-cod-
ing exons 13 (codons 768, 790, and 791), 14 (codons 
804 and 844), and 15 (codon 891) are less common. 
In such cases, MTC appears later, and the prognosis 
is more favorable compared to that of other forms of 
MTC (92) (B). 
However, it is worth noting that individuals from 
the same family who carry the same RET mutation can 
exhibit variable phenotypic expressions and degrees of 
tumor aggressiveness (102) (B). In recent years, the 
presence of RET gene variants or polymorphisms has 
been associated with changes in the clinical presenta-
tion and natural history of MEN 2 (86,105) (D/B). 
Recommendation 9
The knowledge of the type of RET mutation provides 
relevant information about the clinical presentation of 
MEN 2 and the biological behaviors of the associated 
neoplasms (Recommendation B).
10. In addition to endocrine tumors, what are the 
clinical manifestations associated with RET proto-
oncogene mutations?
In addition to pheochromocytoma and hyperpara-
thyroidism, hereditary MTC is rarely associated with 
cutaneous lichen amyloidosis and Hirschsprung’s 
disea se (106-108) (C/B/D).
Cutaneous lichen amyloidosis (CLA) is an itchy 
hyperpigmented skin lesion that appears on the upper 
area of the back (interscapular region). The association 
between mutations in RET codon 634 and CLA was 
first described in 1989 (106) (B). CLA can appear early 
and usually precedes thyroid disease (106,107) (C/B).
Inactivating RET germline mutations appear in 
10-40% of cases of Hirschsprung’s disease; this disease 
comprises the congenital absence of the intestinal in-
termuscular (Auerbach’s), and superficial (Meissner’s) 
and deep (Henle’s) submucosal plexuses, leading to 
symptoms of intestinal obstruction during the neonatal 
period, as well as constipation, abdominal distension, 
and vomiting in adulthood. Mutations in exon 10 are 
associated with the concomitant occurrence of MEN 2 
and Hirschsprung’s disease (108) (B). The affected in-
dividuals carry a single mutation, thus suggesting that 
the effects of that mutation vary as a function of the 
tissues in which RET is expressed (109) (C).
Recommendation 10
The presence of CLA or Hirschsprung’s disease indi-
cates the suspected occurrence of hereditary MTC and 
therefore the need to perform a RET molecular assess-
ment (Recommendation B).
11. When and how to screen for pheochromocytoma 
and hyperparathyroidism? 
MEN 2A is the most common form of MEN and is 
characterized by the occurrence of MTC, pheochro-
mocytoma, and hyperparathyroidism. MTC occurs in 
95% of individuals with MEN 2A, while the risks of 
unilateral or bilateral pheochromocytoma and hyper-
parathyroidism are 57%, and 15-30%, respectively 
(84,110) (D/D). Adrenal disease is usually benign, 
multicentric, and bilateral, and, as a rule, it is detected 
after the onset of MTC. Hyperparathyroidism usual-
ly involves all of the parathyroid glands, and gland 
hyperplasia is the most commonly detected histolo-
gical lesion in early-stage disease. However, when 
diagnosis is delayed, adenoma occurs concomitantly 
with hyperplasia (84) (D). MEN 2B is the less com-
mon variety of MEN 2 and exhibits a more aggressive 
form of MTC, as well as the occurrence of pheochro-
mocytoma; however, hyperparathyroidism does not 
occur (84) (D). 
A recent study assessed the mean age at onset of 
pheochromocytoma in individuals with MEN 2A, ac-
cording to the ATA risk categories described above. 
The authors found that the first pheochromocytomas 
were diagnosed at ages 25, 34, 40, and 56 year old in 
individuals classified as ATA risk levels D, C, B, and A, 
respectively and that the occurrence frequencies were 
27, 32, 17, and 3% in categories D, C, B, and A, re-
spectively (111) (B).
The youngest ages at pheochromocytoma diagnosis 
were 12 and 5 years old in carriers of mutations in codons 
918 and 634, respectively (72,112,113) (B/D/B). Less 
aggressive mutations such as those in codons 609, 611, 
and 618 and in codons 768, 790, and 891 are associa-
ted with a later onset of  pheochromocytoma, specifi-
cally at ages 19 and 28 years old, respectively (72,114) 
(B/B). Therefore, the investigation of adrenal tumors 
in patients with MEN 2 should begin at 8 years of age 
Diagnosis, treatment, and follow-up of medullary thyroid carcinoma
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in carriers of mutations in codons 918, 634, and 630, 
and after 20 years of age in the remainder of the cases 
(72) (B). Assessments might be performed by measur-
ing the plasma or urine metanephrine levels (77-79) 
(B/B/D). The ruling out of pheochromocytoma is of 
paramount importance in cases of hereditary MTC be-
cause the adrenal tumor should be treated before the 
thyroidectomy. 
Hyperparathyroidism rarely occurs in children, as 
the mean age at diagnosis is 38 years old in indivi-
duals with MEN 2A (115,116) (B/B). Serum cal-
cium and albumin measurements should begin at 8 
years of age in carriers of mutations in codons 630 
and 634, and at 20 years of age in carriers of other 
mutations associated with MEN 2A, and should be 
repeated annually. Recently, a case of hyperparathy-
roidism diagnosed in a 5-year-old child with MEN 2A 
was reported (117) (C). 
Recommendation 11 
In asymptomatic cases or in the absence of adrenal mas-
ses, urine and/or fractionated plasma metanephrines 
measurements should begin at 8 years of age in indi-
viduals with MEN 2B or 2A who carry mutations in 
codons 630 or 634, and after 20 years of age in the 
remainder of individuals with MEN 2A.
Hyperparathyroidism screening must be performed 
annually by measuring the total calcium and albumin 
levels, starting at 8 years age in carriers of mutations in 
RET codons 630 and 634 and at 20 years of age in the 
remainder of individuals with MEN 2A.
PART II: MTC – SURgICAL TREATMENT
1. What is the surgical treatment for individuals with 
MTC limited to the thyroid gland?
Upon preoperative assessment, MTC is considered to 
be limited to the thyroid gland if there is no evidence of 
involvement of adjacent structures, or lymph node or 
distant metastases. In such cases, the indicated surgical 
treatment comprises total thyroidectomy with (electi-
ve) prophylactic dissection of the central compartment 
(levels VI and VII; Figure 1) (66,118-120) (B). Given 
the risk of hidden metastatic disease, prophylactic dis-
section of the lateral compartments might be added, 
particularly when the tumor is > 1 cm, if metastases are 
found in the central compartment, or elevated calcito-
nin levels (121-123) (B/B/D).
Recommendation 1 
The surgical treatment recommended for individuals 
with MTC limited to the thyroid gland is total thyroi-
dectomy and elective dissection of the central compart-
ment (Recommendation B).
2. What is the surgical approach for individuals with 
MTC and locoregional disease diagnosed during the 
preoperative assessment?
In individuals with MTC, the presence of locoregional 
disease indicates the need for a total thyroidectomy as-
sociated with dissection of the lymph nodes in the cen-
tral compartment (levels VI and VII; Figure 1) (104) 
(B). Lateral lymph node dissection (levels, II, III, IV, 
and V) is indicated when metastases are suspected in any 
of those levels (121) (B). The benefit of prophylactic 
lateral dissection when metastases are only located in the 
central compartment is controversial. Some authors su-
pport the US preoperative evaluation for the detection 
of metastases and argue against prophylactic dissection. 
However, due to the high incidence of lymph node me-
tastases and the risk of occult metastatic disease, others 
indicate compartment oriented lymph node dissections 
in the first surgery because of the complications associa-
ted with re-interventions (73,121-123) (D/B/B/D).
The current American Joint Committee on Cancer 
(AJCC) 6th edition TNM (tumor, node, metastasis) 
classification system is used for postoperative staging of 
MTC (Table 3) (124). The likelihood of a cure is low 
in cases with extrathyroid disease. The biochemical cure 
Diagnosis, treatment, and follow-up of medullary thyroid carcinoma
Figure 1. Cervical lymph nodes anatomy.
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rates in individuals with preoperative basal calcitonin le-
vels > 300 pg/mL, a primary tumor > 10 mm, and per-
sistent metastatic disease after lymph node dissection are 
below 50% (7) (B). As a rule, only 10-40% of individuals 
with neck metastases achieve biochemical cures (7,119) 
(B), while relapses occur in 3.3% of the individuals who 
attain normal basal calcitonin levels after a follow-up of 
Table 3. American Joint Committee on Cancer TNM Classification
Primary tumor (T)
T0 – No evidence of primary tumor
T1 – Tumor 2 cm or less in greatest dimension limited to the thyroid 
(Supplementum to the 6th edition: T1a, tumor 1 cm or less; T1b, tumor more 
than 1 cm but not more than 2 cm)
T2 – Tumor more than 2 cm, but not more than 4 cm, in greatest dimension 
limited to the thyroid
T3 – Tumor more than 4 cm in greatest dimension limited to the thyroid or any 
tumor with minimal extra-thyroidal extension (e.g. extension to sternothyroid 
muscle or perithyroid soft tissues)
T4a – Tumor of any size extending beyond the thyroid capsule to invade 
subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve
T4b – Tumor invades prevertebral fascia or encases carotid artery or 
mediastinal vessels
Regional lymph nodes (N) are the central compartment, lateral
cervical, and upper mediastinal lymph nodes
NX – Regional lymph nodes cannot be assessed
N0 – No regional lymph node metastases
N1 – Regional lymph node metastases
N1a – Metastasis to Level VI (pretracheal, paratracheal, and prelaryngeal/
Delphian lymph nodes)
N1b – Metastasis to unilateral, bilateral, or contralateral cervical or superior 
mediastinal lymph nodes
Distant metastases (M)
MX – Distant metastasis cannot be assessed
M0 – No distant metastasis
M1 – Distant metastasis
Stage
•	 Stage I:     T1, N0, M0
•	 Stage II:     T2, N0, M0
•	 Stage III:    T3, N0, M0
                      T1, N1a, M0
                      T2, N1a, M0
                      T3, N1a, M0
•	 Stage IVA: T4a, N0, M0
                      T4a, N1a, M0
                      T1, N1b, M0
                      T2, N1b, M0
                      T3, N1b, M0
                      T4a, N1b, M0
•	 Stage IVB: T4b, any N, M0
•	 Stage IVC: any T, any N, M1
Sixth edition (115).
0.7-7.5 years (125) (B). Similar cure rates (~38%) are 
reported in individuals who are subjected to extensive 
surgery (7) (B). Therefore, as extensive surgery is not as-
sociated with higher cure rate, less aggressive procedures 
should be indicated in cases with advanced local disease 
or distant metastases in order to maintain control of local 
disease while preserving the parathyroid function, vocal 
cords, and deglutition (73,104) (D/B).
Recommendation 2 
In cases with locoregional disease, total thyroidectomy 
with central compartment lymph node dissection is in-
dicated (Recommendation B). Lateral lymph node dis-
section is indicated when metastases are present or sus-
pected (Recommendation B). Less aggressive surgery 
should be indicated in cases with advanced local dise-
ase and/or distant metastases to achieve local  disease 
 control while preserving the patient’s voice, degluti-
tion, and parathyroid function (Recommendation B).
3. What is the management of individuals with 
postoperative diagnoses of MTC?
In individuals with MTC that was diagnosed after a total 
lobectomy (thyroid lobe and isthmus), thyroidectomy 
can be complemented by central compartment dissec-
tion or only expectant management in selected cases 
(126,127) (B). According to some authors, the latter 
alternative might apply to individuals with undetecta-
ble calcitonin levels at 2 months after thyroidectomy, 
unifocal MTC limited to the gland, tumor-free surgical 
margins, the absence of C cell hyperplasia, the absence 
of neck lymph node metastases in physical examination 
or on US, and a diagnosis of sporadic MTC based on 
negative RET molecular testing (120,126,127) (B).
Recommendation 3 
Completion thyroidectomy and prophylactic central 
compartment dissection are indicated in patients with 
postoperative diagnoses of MTC (Recommendation B). 
Expectant management might be considered in selec-
ted cases (Recommendation B).
4. What is the approach to the parathyroid glands in 
surgery for MTC?
As a rule, normal parathyroid glands should be preser-
ved when thyroidectomy is performed. However, those 
glands might be accidentally removed or their vascula-
rization might be compromised during surgery, espe-
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cially for those glands located in the lower poles. The 
risk increases when a central compartment dissection 
is performed (124,125) (D/B). When devasculariza-
tion occurs, the affected glands should be grafted onto 
the sternocleidomastoid muscle. In cases with a risk of 
hyperparathyroidism, such as the presence of MEN 2A-
-related mutations, grafting should be performed in the 
non-dominant forearm to facilitate the gland removal 
procedure in the event of recurrent hyperparathyroi-
dism (128-130) (B).
The hyperparathyroidism occurs in approximately 
10 to 20% of patients with MEN 2A. It is usually asso-
ciated with mild and often asymptomatic disease, espe-
cially in young patients. When indicated treatment, it is 
important to establish whether the disease is restricted 
to one or multiple glands and then, decide the most 
appropriate surgical procedure. The following surgical 
procedures may be used, depending on the number of 
glands involved: total parathyroidectomy with auto-
transplantation, subtotal parathyroidectomy, or removal 
of a single gland (128,129) (B). The occurrence of per-
manent hypoparathyroidism is usually associated with 
total parathyroidectomy, although also already been re-
ported after subtotal parathyroidectomy, or even after 
excision of two glands (130) (D). In cases of hyperpara-
thyroidism that appear in individuals who previously 
underwent surgery for MTC, the affected gland should 
be identified via imaging methods such as US, CT, or 
sestamibi scintigraphy before surgery (129,131) (B). 
The successful use of calcimimetics has been reported in 
cases of persistent hyperparathyroidism (132) (B).
Recommendation 4 
In cases without preoperative hyperparathyroidism, 
the “in situ” preservation of the parathyroid glands is 
always desirable. When the glands are accidentally re-
moved or there is a risk of devascularization, the glan-
ds should be autografted into the sternocleidomastoid 
muscle (Recommendation B). In cases with hyperpara-
thyroidism, MEN 2A, or prior surgery for MTC, the 
affected parathyroid gland should be identified with 
imaging methods to decide upon a subtotal or total pa-
rathyroidectomy, followed by a forearm autograft (Re-
commendation B). 
5. What is the surgical approach in asymptomatic 
individuals with RET mutations?
Asymptomatic individuals with RET proto-oncoge-
ne mutations should be assessed before surgery by 
measuring the serum calcitonin levels and using neck 
US to identify the presence of thyroid nodules and 
lymph node metastases, as these indicate the need for 
a different surgical approach (6,64) (B). In such ca-
ses, the ATA guidelines recommend the application 
of a risk categorization system relative to the mini-
mum age at the onset of MTC and the tumor ag-
gressiveness, including the likelihood of metastasis, 
likelihood of cure, morbidity, and mortality (73,133) 
(D). That system clusters codons into risk levels ran-
ging from A (least aggressive) to D (most aggressi-
ve; see Part I: MTC – Diagnosis – Question 8 of 
the present consensus). Based on the risk level that 
corresponds to the affected RET codon, therapeutic 
decision-making is performed according to the best 
age for so-called prophylactic thyroidectomy and the 
need for neck dissection. Preferably, the surgical ap-
proach should be performed in reference centers with 
experienced surgeons and a large volume of thyroid 
surgeries.
Additionally, the likelihood of pheochromocytoma 
onset and the age at which to begin investigating this 
onset are estimated according to those risk levels (see 
Part I: MTC – Diagnosis – Question 6 of the present 
consensus). When pheochromocytoma is diagnosed, it 
should be subjected to surgical treatment before MTC 
(122,134,135) (B).
Recommendation 5
The surgical approach in asymptomatic individuals with 
RET proto-oncogene mutations should consider the 
risk stratification according to the codon that exhibits 
the mutation, as follows: 
– Group D (MEN 2B): total thyroidectomy in 
the first year of life; if there is evidence of lymph 
node metastases, the thyroid nodule is > 5 mm, 
or the serum calcitonin level is > 40 pg/mL, 
central compartment dissection is also indica-
ted. Individuals older than 1 year of age are 
indicated for (elective) “prophylactic” central 
dissection. 
– Group C: total thyroidectomy before 5 years of 
age. 
– Groups A and B: total thyroidectomy after 
5 years of age if there is a lack of evidence for 
MTC (normal basal serum calcitonin levels and 
normal neck US). 
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Individuals in groups A, B, and C should only be 
subjected to central compartment dissection if there is 
clinical and/or imaging evidence of metastatic disease, 
the nodule size is ≥ 5 mm, and the serum calcitonin 
level is > 40 pg/mL (Recommendation B).
6. What is the surgical approach in individuals with 
MTC and distant metastases?
The presence of distant metastases makes a biochemical 
cure of MTC unlikely. For this reason, the presence of 
distant metastases should be carefully assessed when the 
serum calcitonin level is > 400 pg/mL (125,136,137) 
(B/B/D). The surgical treatment of individuals with 
metastatic disease should focus on local disease control 
and mainly on the patients’ quality of life (137) (D).
Recommendation 6 
The surgical treatment of individuals with advanced lo-
cal disease or distant metastases should be less aggressi-
ve and aimed at local disease control, while preserving 
the patient’s voice, deglutition, and the parathyroid 
function and avoiding potential hemorrhagic compli-
cations due to the invasion of vascular structures (Re-
commendation B). 
7. What are the indications for mediastinal lymph 
node dissection in MTC patients?
The mediastinum is divided into a superior portion, 
which is located above the pericardium, and 3 inferior 
divisions, the anterior, middle, and posterior. The mi-
ddle mediastinum contains the heart and pericardium, 
the anterior mediastinum is bounded anteriorly by the 
pericardium and posteriorly by the sternum and con-
tains mainly the thymus, and the posterior mediasti-
num is the area behind the pericardium and contains 
the esophagus and the thoracic aorta, among other 
structures (138) (B). The superior mediastinum con-
tains the thymus and the brachiocephalic artery ante-
riorly and the trachea and esophagus posteriorly. The 
superior mediastinum corresponds to level VII of the 
neck lymph nodes and is included in the dissection of 
the central compartment (104,139) (B). Therefore, 
elective superior mediastinal dissection is usually per-
formed during surgery for MTC via the cervical access. 
The presence of metastases in lymph nodes of inferior 
mediastinum, diagnosed by imaging methods (CT or 
MRI), can be considered as distance metastatic disease, 
which significantly decreases the chance for cure. Thus, 
the dissection of this area should only be offered as a 
palliative treatment in patients with high risk of airway 
obstruction or bleeding (64,121) (B).
Recommendation 7 
Elective superior mediastinal dissection is usually per-
formed during surgery for MTC (Recommendation 
B). The dissection of the lower mediastinum should 
be considered only as a palliative treatment in patients 
with high risk of airway obstruction or bleeding (Re-
commendation B).
8. What is the required preoperative care for 
individuals with MTC and suspected or confirmed 
pheochromocytoma?
In individuals with pheochromocytoma and MTC, 
adrenalectomy should precede thyroidectomy. An in-
vestigation of pheochromocytoma is mandatory in ca-
ses with suspected MEN 2 (72,74,140) (B/B/D) and 
is also indicated in individuals with apparently sporadic 
MTC that has not yet been subjected to RET mole-
cular testing. Although the occurrence of pheochro-
mocytoma is rather unlikely in these cases, its eventual 
identification before thyroid surgery is critical, as the 
complications that arise in undiagnosed cases are severe 
(72,74) (B).
A diagnosis of pheochromocytoma is established 
through the identification of excessive catecholamine 
production by measuring the plasma and/or urine le-
vels of catecholamines and/or metanephrines. The 
measurement of plasma metanephrines seems to be 
most useful in cases of hereditary pheochromocytoma, 
with sensitivity and specificity rates of 99% and 98%, re-
spectively. When a plasma metanephrine measurement 
is not available, urine levels might be assessed (75,76) 
(B). CT or MRI of the abdomen should be performed 
to establish the localization of the pheochromocytoma. 
CT can identify the localization of hereditary adrenal 
tumors in 76% of evaluated cases (80) (B).
Adrenalectomy is indicated for the treatment of 
pheochromocytoma, preferably by laparoscopy after 
appropriate preoperative preparation and before sur-
gery for MTC or hyperparathyroidism. The resection 
of the adrenal medulla (adrenal-sparing surgery), in an 
attempt to preserve the cortex and avoid adrenal in-
sufficiency, should be considered in cases of bilateral 
pheochromocytoma (73,140) (D). A recent multi-
center study involving a large number of patients with 
MEN 2A-associated pheochromocytoma showed that 
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the recurrence rate in these cases is low (3%), when per-
formed in specialized centers (141) (B). Preparation for 
surgery should be individualized according to patient 
symptomatology. In general, it is recommended the use 
of alpha-blockers for 1-2 weeks to reduce systemic va-
soconstriction (140) (D). Release salt intake and / or 
saline infusion may also be indicated for the expansion 
of blood volume (140) (D).
Recommendation 8
A proper investigation is needed to confirm or rule out 
the presence of pheochromocytoma before thyroidec-
tomy (Recommendation B). In individuals with pheo-
chromocytoma and MTC, adrenal surgery should pre-
cede thyroidectomy (Recommendation B). 
PART III: MTC – FOLLOW-UP
1. Which tests should be performed during the 
postoperative follow-up of individuals with MTC?
After surgery, patients should be assessed regarding the 
presence of residual disease, the localization of metasta-
ses, and the identification of progressive disease. 
Measurements of the serum levels of calcitonin 
and CEA are of paramount importance during the 
postoperative follow-ups of individuals with MTC be-
cause these biomarkers might indicate the presence 
and volume of residual disease (142) (B). However, as 
their nadirs might occur after several weeks (142,143) 
(B/C), measurements should be performed at least 2-3 
months after surgery.
The specificities of immunometric assays for calci-
tonin measurement that use 2 monoclonal or 1 mono-
clonal and 1 polyclonal antibody are 95-100% (40,41) 
(B/A). To avoid mistakes in the interpretation of re-
sults, it should be noted that the absolute values pro-
vided by different assays might not be fully comparable. 
Additionally, the possibility of a hook effect or non-
calcitonin-secreting tumors should be considered (false 
low calcitonin levels) (38,39) (C). 
The calcitonin levels might decrease from 24 hours 
to 4 weeks after surgery, but this could also occur se-
veral months later in some cases (142,144,145) (B). 
Persistently high calcitonin levels might be found in 
patients with kidney failure or liver cirrhosis and MTC, 
due to an increase in the hormone half-life caused by 
decline of the renal or hepatic function, thus requiring 
a differential diagnosis with an actual increase in secre-
tion due to a persistent thyroid neoplasm (146,147) 
(C/D). 
In most individuals with sporadic MTC, the calci-
tonin levels tend to remain high due to residual disea-
se. The likelihood of attaining undetectable calcitonin 
levels is 83-95% in individuals without lymph node 
metastases who were subjected to thyroidectomy and 
neck dissection, but the frequency decreases to 21-
30% when neck lymph node metastases are present 
(9,121,148) (B).
Although also CEA behaves as a marker of MTC, its 
levels are not always elevated in all patients and do not 
systematically correlate with the calcitonin levels. The 
CEA levels might return to normal values after surgery, 
even in the presence of elevated calcitonin levels; this 
might be due to the presence of small residual neo-
plastic foci. In contrast, in individuals with progressive 
disease, the CEA levels might increase without a cor-
responding elevation in the calcitonin levels. Increased 
serum CEA levels are considered to indicate a poor 
prognosis (149) (C).
Recommendation 1
Measurements of serum calcitonin and CEA should 
be performed 2-3 months after surgery (Recommen-
dation B). If normal calcitonin values are observed, 
these measurements should be repeated 6-12 months 
later. Persistently calcitonin/CEA levels are suggestive 
of persistent or recurrent disease. In such cases, an in-
vestigation must be continued to establish the extent 
of disease. 
2. Which factors determine the prognosis of 
individuals with MTC?
The likelihood of attaining a cure for MTC mostly de-
pends on the tumor stage at the time of diagnosis and a 
full surgical resection. The main factors associated with 
poor prognosis include an older age at diagnosis, the 
primary tumor size, the presence of local and distant 
metastases, the presence of somatic mutations, and the 
calcitonin doubling time (150-152) (B).
The most recent data about the 10-year survival 
rates for MTC are 95.6%, 75.5% and 40% for patients 
with tumors confined to the thyroid, local and distant 
metastases, respectively (12) (B), and are similar to 
those previously reported (100%, 93%, 71% e 21%, for 
stages I, II, III e IV, respectively) (153) (B). The sur-
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vival rates are higher, the regional control of disease is 
better, and the occurrence of distant metastases is less 
frequent in individuals < 45 years of age (154) (B). 
A tumor size < 0.5 cm correlates with the absence of 
postoperative clinically or laboratory detectable disease 
(155) (B). 
Stage T4b tumors and/or the presence of lymph 
node and/or distant metastases are associated with 
lower remission and survival rates (156) (B). Addition-
ally, the localization of metastases influences the prog-
nosis; for example, bone metastases are associated with 
a poorer prognosis, compared to metastases in soft tis-
sues (11) (B).
Prophylactic thyroidectomy is indicated in all RET 
mutation carriers, and minimally invasive surgery might 
be considered in asymptomatic carriers. The type of 
RET mutation correlates with the biological beha-
vior of MTC, and therefore identifying the mutation 
type might facilitate decision-making with respect to 
the most adequate age for and the extent of surgery 
(73,99) (D/C). The use of prophylactic surgery im-
proves the cure rates (100) (B). In individuals with he-
reditary MTC, a palpable thyroid nodule and lymph 
node metastases at the time of diagnosis are associated 
with persistent disease (100) (B).
The calcitonin and CEA levels might remain steadi-
ly high for several years or might exhibit rapid and pro-
gressive increases. Serial calcitonin and CEA measure-
ments allow a more accurate assessment of the marker 
levels through calculations of their doubling times 
(DT); these might be performed with a tool available 
at the ATA website (http://www.thyroid.org/thyroid-
physicians-professionals/calculators/thyroid-cancer-
carcinoma/). The calcitonin DT has prognostic value 
in individuals with MTC, as it correlates with the sur-
vival and tumor recurrence rates (157) (B). A calcitonin 
DT calculation requires a minimum of 4 measurements 
at 6-month intervals. The 5 and 10 – year survival 
rates are 25% and 8%, respectively, when the DT is < 6 
months, and 92% and 37%, respectively, when the DT 
ranges from 6 months to 2 years. The prognosis was 
found to be even more favorable in individuals with a 
DT > 2 years (158) (B). 
CEA is a less specific marker of MTC, and the com-
parison of its DT relative to that of calcitonin revealed 
diverging results. In one study that compared those 
markers in a multivariate analysis, both markers be-
haved as independent predictors of survival; however, 
the calcitonin DT had a better performance (158) (B). 
In contrast, according to another study, the CEA DT 
had a greater impact on prognosis (159) (B). Those 
conflicting results notwithstanding, both markers are 
useful and allow the identification of high-risk indi-
viduals. Therefore, when the calcitonin and CEA DTs 
indicate rapidly progressing disease, a more thorough 
assessment that includes imaging tests should be con-
sidered whenever possible to localize the disease and 
indicate the proper treatment. 
Recently, Tuttle and Ganly (137) (D) formulated 
a novel approach to the assessment of postoperative 
MTC progression, consisting of a dynamic risk stratifi-
cation similar to that developed for well-differentiated 
thyroid carcinomas (Table 4). An excellent response is 
defined as undetectable calcitonin levels after adequate 
surgical treatment, and the likelihood for achieving 
such responses is greater when the preoperative calcito-
nin and CEA levels are low, the primary tumor is small, 
there are no neck metastases, and the disease is in an 
early stage. Under such conditions, the 5 and 10 – year 
recurrence rates vary from < 1 – 8.5%, and the survival 
rates after surgery are 97-99% at 5 years and 95-97% at 
10 years (137,160,161) (D/B/B).
Diagnosis, treatment, and follow-up of medullary thyroid carcinoma
Table 4. Risk stratification system for evaluation of medullary thyroid 
carcinoma after initial therapy
Response to initial therapy Definitions
Excellent No clinical, imaging or biochemical evidence 
of disease
Biochemical incomplete Increased levels of tumor makers (calcitonin, 
CEA), without structural evidence of the 
disease
Structural incomplete Persistent anatomical disease; presence 
distant metastases
Indeterminate Unspecific abnormalities on imaging tests, 
non-normalized tumor marker levels, or no 
detectable evidence of anatomical disease
Incomplete responses are exhibited by 45-70% of 
the cases and are characterized by evidence of persistent 
disease after the initial treatment (73,136,137,161) 
(D/B/D/B). Additionally, the presence of distant me-
tastases after the initial treatment is considered an in-
complete response to the initial treatment. The 5 and 
10 – year survival rates of individuals with persistently 
elevated calcitonin levels are 80-86% and 70%, respec-
tively (153,161-163) (B/A). The cases with unspecific 
abnormalities on imaging tests, non-normalized tumor 
marker levels, or no detectable evidence of anatomical 
and biochemical disease are classified as indeterminate 
responses (137,164) (D/B).
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Recommendation 2
The main prognostic factors of survival in indivi duals 
with MTC are age, the tumor stage at the time of 
diagnosis, and the calcitonin and CEA doubling times 
(Recommendation B). In individuals with hereditary 
MTC, the main prognostic factor of cure and survi-
val is the performance of a prophylactic thyroidectomy 
following the identification of RET gene mutations 
(Recommendation B).
3. Which tests should be performed in individuals 
with persistently detectable calcitonin levels after 
initial surgery?
The postoperative serum calcitonin levels determine 
the strategies used for further assessments. Calcitonin 
levels < 150 pg/mL correlate with the presence of lo-
coregional disease, but the likelihood of distant metas-
tases is low or they are few in number (68,165) (B). 
The initial assessment test is neck US. The rate of lo-
cal MTC relapse might be as high as 58% (62,68,166) 
(B/B/D). The sensitivity of neck US for diagnos-
ing locoregional metastases is 97%, compared to 72% 
with CT and 55% with positron emission tomography 
(PET)-CT (10) (B). When suspected metastatic lymph 
nodes are found, a puncture biopsy might help to elu-
cidate the diagnosis, and the sensitivity and specificity 
of this test increase when calcitonin is measured in the 
washout fluid (22) (B). CT can identify 100% of the 
cases with mediastinal lymph node involvement, versus 
65% with PET-CT (10) (B). 
The presence of distant metastases might be inves-
tigated with CT of the neck and/or chest, MRI, bone 
scintigraphy, and [18F]-fluorodeoxyglucose (18F-FDG) 
PET-CT. The sensitivities of these tests for detecting 
metastatic disease vary from 50-80%. The likelihood 
of identifying metastatic disease is lower in individu-
als with discrete calcitonin elevation (10,167-170) (B), 
but high when the calcitonin levels exceed 150 pg/mL 
(165) (B).
The median calcitonin levels in individuals with 1 
and 2-4 metastatic sites are 1,510 pg/mL and 18,450 
pg/mL, respectively (165) (B). The most frequent sites 
of distant metastasis are the liver (49%), bones (45%), 
and lungs (35%) (10) (B). The sensitivities of CT and 
US for diagnosing liver metastases are similar (90% and 
85%, respectively), but lower than that of MRI (100%) 
(10) (B). Bone scintigraphy is indicated for investigat-
ing low-mechanical risk lesions (ribs, sternum, clavicles, 
and skull), and axial skeleton MRI is indicated for high-
mechanical risk lesions (spine, pelvic bones, and long 
bones). CT is the most accurate method for diagnosing 
lung metastases. Therefore, the best test combination 
for detecting distant metastases includes chest CT, liver 
MRI, and bone scintigraphy and/or axial skeleton MRI 
(10) (B).
Experiences with the use of [18F]-dihydroxyphenyl-
alanine (18F-DOPA) PET in metastatic MTC remain 
limited. This method has a sensitivity rate of 63% and 
might be used to investigate metastases in cases of 
slowly progressive MTC (168,171) (B). Metaiodoben-
zylguanidine (MIBG) scintigraphy might be useful in 
some cases, while somatostatin receptor scintigraphy is 
an additional option when the serum calcitonin levels 
are > 800 pg/mL (172) (B).
In individuals with high calcitonin levels and nega-
tive imaging tests, 18F-FDG PET-CT had sensiti-
vity, specificity, and diagnostic accuracy rates of 88%, 
84.6%, and 87%, respectively, for the detection of oc-
cult recurrences of MTC (173) (B). In a comparison 
of 18F-FDG, 18F-DOPA, and 68Ga-somatostatin ana-
logue PET-CT in individuals with recurrent MTC, the 
metastatic lesion detection rates were 28%, 85%, and 
20%, respectively. According to those data, 18F-DOPA 
PET-CT seems to be the most useful method for de-
tecting MTC recurrences in individuals with elevated 
serum calcitonin levels (174) (B). However, other 
studies showed no significant differences between 
PET 18F-DOPA and 18F-FDG in the same population 
(175) (B).
Recommendation 3 (Flowchart 2)
Basal calcitonin levels < 150 pg/mL are associated 
with the presence of locoregional disease, and neck US 
should be the first test used in the assessment (Recom-
mendation B). The likelihood of detecting distant me-
tastases is higher among patients with calcitonin levels > 
150 pg/mL. In such cases, chest CT, abdominal MRI, 
and bone scintigraphy should be performed to establish 
the presence of mediastinal and lung, liver, and bone 
metastases, respectively (Recommendation B).
4. Which tests should be performed during the 
follow-up of individuals with undetectable calcitonin 
levels after surgery?
Serum calcitonin is the most sensitive marker of resi-
dual MTC after surgery. According to some studies, 
the calcitonin levels are below the threshold of de-
tection in 100% of the individuals subjected to total 
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5. When is the pentagastrin or calcium stimulation 
test for calcitonin indicated in patients already 
subjected to surgery?
In some individuals with undetectable basal calcitonin 
levels, pentagastrin and/or calcium stimulation might 
increase these levels, thus indicating the presence of 
residual disease. However, the localization of residual 
disease is very difficult to establish with imaging me-
thods in the vast majority of such cases (134,176,178) 
(B/B/C). Further disadvantages associated with these 
stimulation tests are their costs, side effects, and the 
unavailability of pentagastrin in Brazil. 
Recommendation 5
The pentagastrin/calcium stimulation test is not indi-
cated for the follow-up of individuals with undetectable 
basal serum calcitonin, as positive results denote resi-
dual diseases that are difficult to locate with imaging 
methods (Recommendation B).
6. What should comprise the management of 
patients with persistently detectable calcitonin 
levels after primary surgery?
Curative reoperation (to achieve undetectable serum cal-
citonin levels) is indicated in individuals who exhibit evi-
dence of persistent disease due to an incomplete primary 
surgery or a disease recurrence in the neck. The presence 
of inoperable distant metastases should be ruled out be-
fore a cervical reoperation is considered. Surgery might 
also have palliative indications in cases with the risk of 
compression or invasion of the trachea or the great ves-
sels (179) (D). Expectant management, including perio-
dical clinical and laboratory assessments, is indicated in 
cases of indolent disease that have already been subjected 
to appropriate surgical treatments (179) (D). Follow-up 
measurements of serum calcitonin in individuals with 
MTC might determine the later management.
Discrete increases in the calcitonin levels (< 150 
pg/mL) at 2-3 months after surgery are associated 
with locoregional disease or small distant metastases in 
most cases (68,165) (B). When residual or recurrent 
disease is detected in the neck, surgical reintervention 
should be considered. The rates of calcitonin norma-
lization  after cervical reoperation vary from 16-38% 
(180-184) (B). A retrospective study found that reo-
peration allowed the identification of residual disease 
in the lateral lymph nodes in 64% of cases, in the cen-
tral compartment in 22%, and in the anterior medi-
Diagnosis, treatment, and follow-up of medullary thyroid carcinoma
MTC
Post-surgery
Calcitonin and CEA measurements
Serum calcitonin 
undetectable (< 2 pg/mL)
Neck US
Additional evaluation 
if necessary
Neck US
throrax CT, liver
MRI, bone scan, MRI
axial skeleton
< 150 ng/dL ≥ 150 ng/dL
Repeated measurements
at 6-12 months
of follow up
Elevated serum
calcitonin
Flowchart 2. Evaluation of patients with medullary thyroid carcinoma 
post-surgery.
thyroidectomy (176) (B). The likelihood of residual/
recurrent disease in individuals with undetectable ba-
sal and post-pentagastrin stimulation calcitonin levels 
after surgery was reported to be approximately 3% 
(125) (B). 
The likelihood that calcitonin levels will become 
undetectable after total thyroidectomy is 95% in indivi-
duals with thyroid gland-restricted disease. The pres-
ence of neck metastases reduces the likelihood that 
calcitonin will return to normal values to 30% (9). Al-
though the average time for the recurrence of MTC 
is 3.2 ± 2.2 years, the calcitonin levels should be mea-
sured every 6-12 months for a still-undefined period of 
time, including after they have become undetectable af-
ter surgery, due to the risk of disease relapse (125) (B). 
It is worth observing that a few cases of indivi duals 
with advanced MTC and normal serum calcitonin lev-
els were reported (39,177) (C). Those patients’ follow-
ups should include imaging modalities. Measurements 
of the calcitonin levels in the FNAB washout fluid 
might facilitate the proper diagnoses of suspected MTC 
metastatic lesions (22,23) (B/C).
Recommendation 4
Measurements of serum calcitonin levels should be per-
formed every 6-12 months for a still-undefined  period 
of time in individuals with undetectable levels after 
surgery due to the risk of disease relapse (Recommen-
dation B). Measurements of the calcitonin level in the 
FNAB washout fluid might facilitate the diagnoses of 
suspected lesions (Recommendation B).
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astinum in 14% of cases. The serum calcitonin levels 
returned to normal in only 6% of the investigated indi-
viduals; however, the remainder of the sample exhib-
ited 50% reductions or stabilization of the calcitonin 
levels (181) (B). Another study followed up individu-
als who were subjected to reoperation for MTC over 
a period of 8-10 years and found calcitonin levels < 
10 pg/mL in 26% of the participants and < 100 pg/
mL in an additional 20.4% of patients. Disease could 
not be detected with imaging methods in any of those 
individuals (184) (B). 
Although reoperation might reduce the disease 
progression in selected individuals, a biological cure of 
MTC is seldom achieved in such cases. For that reason, 
the surgical approach to recurrent or persistent MTC 
in individuals with no or minimal distant metastases 
should include dissection of the affected central (level 
VI) or lateral (levels IIA, III, IV, and V) compartments. 
Expectant management is recommended for cases in 
which the anatomical localization of the metastases 
cannot be established (179). 
Significantly elevated calcitonin levels (> 150 pg/mL) 
at 2-3 months after surgery are usually associated with 
the presence of distant metastases, and the higher the cal-
citonin level, the higher the likelihood of identifying the 
lesion localization (185) (B). As a rule, the management 
of individuals with calcitonin levels > 150 pg/mL is simi-
lar to that of patients with lower levels (186) (D). 
The therapeutic strategy for individuals with locore-
gional and distant metastases should be decided on an 
individual basis, while considering the indolent course 
of MTC and the morbidity associated with the available 
treatments. The presence of neck lymph nodes < 1 cm 
and asymptomatic distant metastases does not suggest 
a need for intervention, as treatment has not proven 
bene ficial in such cases. Possible therapeutic options 
include surgery, percutaneous interventions, liver me-
tastasis embolization, radiotherapy, and tyrosine-kinase 
inhibitors (187) (D). It is worth observing that the like-
lihood of a cure in individuals with distant metastases is 
minimal. The relative risks and benefits of any procedure 
should be carefully assessed when deciding whether pal-
liative therapy or watchful waiting is indicated.
Recommendation 6
Serum calcitonin is the most relevant biomarker for the 
follow up individuals with MTC (Recommendation B). 
Discrete increases in the calcitonin levels (< 150 pg/
mL) usually denote the presence of locoregional dise-
ase (Recommendation B). More substantial elevations 
(> 150 pg/mL) are suggestive of distant metastases 
(Recommendation B). The best methods for investiga-
ting metastases are US for the neck, CT for the chest, 
MRI for the liver, and bone scintigraphy and/or axial 
skeleton MRI for the bones (Recommendation B). 
A new surgical procedure should be considered in 
presence of residual or recurrent local disease (Recom-
mendation B). In patients with distant metastases, the 
treatment strategy should be individualized, taking 
into consideration the indolent course of CMT and the 
morbidity associated with available therapies (Recom-
mendation D).
7. What is the appropriate management for 
individuals with increased calcitonin levels and 
negative imaging tests?
Individuals with detectable calcitonin levels after sur-
gery should be assessed with imaging methods to lo-
cate the disease site. When imaging tests fail to identi-
fy the disease foci, the patients should be subjected to 
periodical assessments at intervals determined by the 
calcitonin and CEA DT, as these are markers of disease 
progression (158,165) (B). To calculate the DTs, the 
serum calcitonin and CEA levels should be measured 
every 6 months, and the ideal interval for assessments 
of individuals with MTC corresponds to one-fourth of 
the DT or each year, whichever is shorter. 
Recommendation 7
Individuals with elevated serum calcitonin levels and 
negative imaging tests should be assessed at least every 
6 months, and these assessments should include mea-
surements of the calcitonin and CEA levels to calculate 
their DTs (Recommendation B).
8. What should comprise the treatment of individuals 
with MTC and distant metastases?
The following questions should be considered during 
decision-making, with respect to the best management 
of individuals with metastatic MTC:
•	 Is the patient symptomatic or asymptomatic?
•	 Where are the metastases located?
•	 Are there lesions that require intervention due 
to imminent risk or associated symptoms (e.g., 
brain lesions, painful bone lesions or those with 
a risk of fracture, or chest pain and the risk of 
bronchial obstruction)?
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•	 Is the locoregional disease controlled?
•	 What is the speed of metastatic disease progres-
sion?
The treatment of distant metastases is indicated in 
cases associated with an imminent risk of serious com-
plications such as brain metastases, lesions that cause 
spinal cord compression or airway affection, hormone-
secreting metastases, or bone metastases that exhibit an 
active or imminent risk of fracture. Expectant manage-
ment might be indicated in asymptomatic individuals 
who exhibit small indolent metastases. Patients with 
rapidly progressive disease, as evidenced by imaging 
or laboratory testing, are candidates for systemic novel 
drug treatment. 
The disease progression speed might be assessed from 
the calcitonin and CEA DTs or imaging results that have 
been interpreted according to the Response Evaluation 
Criteria In Solid Tumors (RECIST), in which increases 
> 20% in the sum of the lesions’ diameters are classified 
as progressive disease (158,165,188) (B). 
Recommendation 8
Systemic treatment should be considered for sympto-
matic individuals and/or those with documented sig-
nificant disease progression (according to radiological 
methods and/or a calcitonin or CEA DT < 6 months) 
(Recommendation B).
9. What should comprise the treatment of individuals 
with hormone-secreting metastases?
The ectopic production of corticotropin-releasing 
hormone (CRH) and adrenocorticotropic hormo-
ne (ACTH) and the secretion of VIP, insulin, and 
glucagon were described in individuals with MTC 
(52,53,189,190) (B/B/D/C). 
Diarrhea might appear due to increased intestinal 
motility (191) (C) or the hypersecretion of calcitonin 
and/or VIP (52,192) (B/C). According to recom-
mendations, treatment should initially include antimo-
tility agents (loperamide or codeine). Further options 
for unsuccessful cases include the use of somatostatin 
analogues (193-195) (B) and the selective resection 
or arterial chemoembolization of liver metastases to 
reduce the hypercalcitonemia caused by those lesions 
(196,197) (B/C).
MTC comprises 2-6% of ectopic Cushing’s syn-
drome cases (198,199) (B/C), and treatment might 
include surgery or chemoembolization for liver metas-
tases. Additionally, adrenolytic drugs (ketoconazole, 
milotane, or metyrapone) might be used, while bila-
teral adrenalectomy is indicated in uncontrolled cases 
(198-200) (B/C/C). Recently, it has been reported 
a sorafenib-induced reduction of cortisol and ACTH 
levels, associated with dramatic clinical improvement, 
in a patient with advanced MTC and ectopic ACTH 
syndrome (201) (C).
Recommendation 9 
Advanced MTC metastatic disease might be atten-
ded by systemic hormonal changes secondary to the 
increa sed calcitonin levels and/or the ectopic produc-
tion of some specific hormones. Treatment should be 
planned on an individual basis according to the clini-
cal manifestations of the existing dysfunction (Recom-
mendation B).
10. What are the indications for chemotherapy and/
or radiotherapy in the management of individuals 
with metastatic MTC?
Radiotherapy
The role of radiotherapy in the treatment of MTC is 
rather limited (202-204) (B/B/D). In individuals at 
a high risk of local recurrence (locally invasive tumors, 
microscopic residual disease, and neck lymph node in-
volvement), radiotherapy was shown to reduce the lo-
cal recurrence rate in 86% of patients at a 10 – year 
follow-up (205) (B).
The indication for radiotherapy in systemic meta-
static disease is restricted to the palliative treatment of 
painful bone metastases or those at risk of fracture, as 
described for bone metastases secondary to other types 
of tumors (206) (B), and to the treatment of hemoptysis 
or airway obstruction in individuals with extensive medi-
astinal and/or lung involvement (204,207) (D/C).
Systemic chemotherapy
The results of studies of single or combined chemo-
therapy agents have not been satisfactory. No phase 
III studies with large numbers of patients have been 
conducted. A combination of doxorubicin, dacarbazi-
ne, and streptozocin induced partial responses in 15% 
of a sample of individuals with MTC (208,209) (B). 
Additionally, the results were limited in studies that 
used cyclophosphamide, vincristine, cisplatin, and bleo-
mycin (208,210-212) (B). Therefore, as conventional 
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chemotherapy has not been effective, it is exclusively 
recommended for selected individuals with rapidly pro-
gressive metastatic disease. 
Recommendation 10
Radiotherapy should be considered for local disease con-
trol (Recommendation B), the palliative treatment of 
painful bone metastases or those at risk of fracture (Re-
commendation B), and for the treatment of hemoptysis or 
airway obstruction in individuals with extensive mediasti-
nal and/or lung involvement (Recommendation D). The 
effects of conventional chemotherapy are limited, and thus 
it should only be considered in selected cases (significant 
progression of the tumor mass) (Recommendation B).
11. What new drugs are available for the 
management of individuals with metastatic MTC?
In recent years, cumulative knowledge about the mo-
lecular mechanisms and intracellular signaling pathways 
involved in the pathogenesis of neoplasms such as 
MTC has allowed the development of novel targeted 
therapies. 
Uncontrolled tyrosine-kinase receptor activation is 
one of the main mechanisms involved in cancer develop-
ment and progression (213,214) (D). Vascular endo-
thelial growth factor (VEGF) performs critical func-
tions in physiological and pathological angiogenesis, 
as well as in lymphangiogenesis (215) (D). Inhibition 
of VEGF action by blocking its receptors represents a 
novel approach to anticancer therapy (213,216,217) 
(B/D/D). Recent studies conducted with novel drugs 
that inhibit VEGF and its receptors in thyroid tumors 
yielded satisfactory results (218). In addition to VEGF, 
MTC pathogenesis also involves the presence of soma-
tic or germline mutations in the RET proto-oncogene. 
RET comprises 21 exons and encodes a tyrosine-kinase 
receptor that is expressed in neural crest-derived cells 
(2,4) (D). Therefore, the use of drugs with anti-tyro-
sine kinase activities represents a novel therapeutic op-
tion for MTC management. 
The initial results of clinical studies that used novel 
drugs such as tyrosine-kinase inhibitors to treat MTC 
were published in 2008 (www.clinicaltrials.gov). Clini-
cal trials that employ such agents use RECIST to as-
sess the responses to treatment as follows: complete 
response (disappearance of all target lesions), partial 
response (at least a 30% reduction in the sum of the 
longest target lesion diameters), progressive disease (at 
least a 20% increase in the sum of the longest target 
lesion diameters), and stable disease (neither sufficient 
shrinkage to qualify as a partial response nor sufficient 
increase to qualify as progressive disease) (219) (D).
Overall, the partial response rate is approximately 
30%, whereas stable disease is the most commonly 
achieved outcome. Two tyrosine-kinase inhibitors have 
been approved by the FDA (U. S. Food and Drug 
Administration) to treat rapidly progressive meta-
static MTC, specifically vandetanib and cabozantinib 
(http://www.fda.gov/); however, only the former has 
been approved in Brazil. 
Vandetanib is an oral agent that selectively targets the 
RET receptor, VEGF receptors (VEGFR), and the epider-
mal growth factor receptor (EGFR) (220,221) (D/D). A 
phase III clinical trial assessed the efficacy of vandetanib 
in 331 individuals with metastatic MTC who were ran-
domized to receive vandetanib (300 mg) or a placebo. 
The results showed a significant increase in progression-
free survival in the vandetanib-treated group, compared 
to the placebo group (30.2 vs. 19.2 months, respectively; 
hazard risk (HR) = 0.46, 95% confidence interval (CI) = 
0.31-0.69). The rate of mortality at 2 – year follow-up 
was 15% (222,223) (B). Another Phase II clinical study 
evaluated 19 patients using a reduced dose of vandetanib 
(100 mg/d). In this small group of patients, vandetanib 
used was associated with decreased progression-free sur-
vival with fewer adverse effects (224) (B). This same dose 
(100 mg/d) was also successfully used in children with 
MEN 2B (225) (B). A recent systematic review on the 
use of vandetanib in MTC indicates the medication in pa-
tients with loco regional disease unresectable, symptoma-
tic distant metastatic disease and disseminated metastatic 
disease (226) (B). Preclinical studies have indicated that 
RET codon 804 mutations (V804L, V804M) induce re-
sistance to vandetanib (227) (B).
Cabozantinib (XL184) is a powerful inhibitor of the 
hepatocyte growth factor receptor (MET), VEGFR2, 
and RET. A multicenter randomized study of 300 in-
dividuals with documented MTC progression during 
the previous 14 months found a significant increase in 
progression-free survival in the cabozantinib-treated 
group (140 mg/d), compared to the placebo group 
(11.2 vs. 4.0 months, respectively; RR = 0.28, 95% CI 
= 0.19-0.40, p < 0.0001) (228,229) (B). 
The effect of vandetanib or cabozantinib on the 
survival rate of MTC patients remains unknown, but 
interim analyses of the overall survival did not show a 
difference between the study drug-treated and placebo 
groups (222,228) (B/B).
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Table 5 summarizes the main available drugs, as well as 
their corresponding targets and outcomes (222,228-242) 
(B/B/B/C/B/C/B/C/C/B/C/B/C/C/B/C).
The most common side effects of the tyrosine-
kinase inhibitors include diarrhea, nausea, skin rash, 
hypertension, and fatigue (243) (D). Additionally ad-
verse events include neutropenia, leukopenia, hand-
foot syndrome, stomatitis, proteinuria, abdominal 
pain, face swelling, thrombocytopenia and QTc pro-
longation – it is suggested that patients be monitored 
by conducting periodic electrocardiograms. The levo-
thyroxine dose for replacement therapy usually needs 
to be increased. As a rule, the side effects of these 
inhibitors are well tolerated, and toxicity is control-
lable in most individuals. Nevertheless, severe adverse 
events have also been reported, including aspiration 
pneumonia, respiratory failure, septicemia, acute 
heart failure, and arrhythmia (222,231,236,244-248) 
(B/B/B/B/C/C/B/C).
 Other therapeutic approaches for metastatic MTC 
are currently being investigated, including anti-CEA 
antibody-targeted radiotherapy, gene therapy, and other 
radiopharmaceuticals. Currently, such medications are 
only used in research protocols (249,250) (D/D).
Recommendation 11
The results reported to date indicate that tyrosine-ki-
nase inhibitors represent a relevant therapeutic option 
for the treatment of locally advanced or metastatic 
MTC (Recommendation A). Nevertheless, the cor-
responding data regarding long-term survival are not 
yet available. As a function of their side effect profiles, 
caution is required when identifying patients who mi-
ght benefit from these drugs (Recommendation D). 
Currently, two tyrosine-kinase inhibitors, vandetanib 
and cabozantinib, have been approved by the FDA for 
the treatment of rapidly progressive metastatic MTC, 
while only the former has been approved in Brazil. 
12. What should comprise the management of 
distant metastases?
Bone metastases
The incidence of bone metastases in thyroid carcinoma 
is approximately 5.0%, with median survival time after 
metastasis of 5.3 ± 1.3 years; patients with hypercalce-
mia have lower survival (251) (B). The term skeletal-
-related event (SRE) is used to quantify the morbidity 
associated with bone metastases. The clinical determi-
nants that compose the SRE include spinal cord com-
pression, pathologic fractures, and the need for external 
radiotherapy or surgery to afford pain relief or control 
tumor-related hypercalcemia. Imaging exams are essen-
tial to determine the location and extent of the bone 
lesions; skeletal CT or MRI and FDG-PET/CT are the 
best currently available methods (10,252) (B/D)
The management of bone metastases depends on 
their number, localization and associated symptoms. If 
the disease is localized, surgical resection significantly 
improves patient prognosis and survival, and may be 
curative (253) (D). Spinal cord compression indicates 
emergency surgery and the use of systemic corticoste-
roids. Active or imminent fractures in body-supporting 
bones require surgical treatment. Radiotherapy is useful 
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Table 5. Tyrosine kinase inhibitors for treatment of medullary thyroid carcinoma
Drugs approved Targets Patients (n) Dosea
PFS drug vs.
Placebo 
(months)
Hazard 
Ratiob References
Vandetanib (ZD6474) VEGFR-1, VEGFR-2, VEGFR-3, RET, EGFR 331 300 mg 30.5 vs. 19.3 0.46 222
Carbozantinib (XL 184) VEGFR-2, RET, MET 330 140 mg 11.2 vs. 4.0 0.28 228,229
Investigational drugs Targets Patients (n) Dosea
Partial 
response
(%)
Stable 
Diseasec 
(%)
References
Montesanib (AMG 706) VEGFR-1, VEGFR-2, VEGFR-3, C-KIT, RET, PDGFR 91 125 mg 2 48 230,231
Sorafenib (BAY 43-9006) VEGFR-2, VEGFR-3, c-Kit, RET 21 400 mg 6 50 232,233
Sunitinib (SU 11248) VEGFR-1, VEGFR-2, VEGFR-3, RET, c-Kit 7 37,5 mg 28 46 234,235,236
Axitinib (AG-013736) VEGFR-1, VEGFR-2, VEGFR-3, c-Kit 11 5 mg 18 27 237,238
Imanitib (STI571) RET, c-Kit, PDGFR 9 600 mg 0 55 239,240
15 600 mg 0 27 241
a. The drugs were used once daily, except for the treatment with sorafenib; axitinib were administered twice daily.
b / c. Results are expressed as hazard ratio of objective response (b; drug vs. placebo) and rate of disease control (c).
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for painful bone metastases, when surgery is contraindi-
cated, or if resection was incomplete (252,253) (B/D).
The indication of bisphosphonates given per the in-
travenous route for the control of bone metastasis-related 
pain has been well established in other solid and hema-
tological malignancies (254-256) (B). One recent study 
showed that zoledronic acid could effectively reduce ske-
letal-related events, including bone fractures, spinal cord 
compression, and hypercalcemia in individuals with differ-
entiated thyroid carcinoma and bone metastases (257) (B).
Liver metastases
The liver is the most frequent site of MTC metastases. 
The overall survival of patients with liver metastases who 
underwent radiofrequency ablation was 6 years (258) 
(B). The lesions are usually multiple and disseminated 
(259) (B). Treatment should be considered for large or 
progressive lesions, as well as for those associated with 
the occurrence of diarrhea and/or pain. The available 
options for treatment include chemoembolization (40-
60% achieve partial response/disease stabilization) and 
tyrosine kinase inhibitor therapy for progressive disease 
(197,243) (C/D).
Lung and mediastinal metastases
Mediastinal lymph node involvement is frequent in ad-
vanced MTC, and its presence usually indicates an incu-
rable disease. Therefore, when the lymph node affection 
is stable and not associated with clinical manifestations, 
expectant management is indicated, and the patients 
should be monitored with imaging methods and mea-
surements of the calcitonin/CEA levels (188) (B).
When airway compression or bleeding occur, sur-
gery, radiotherapy, or radiofrequency ablation should 
be considered for the management of lung and/or me-
diastinal metastases (260) (D).
Brain metastases
Individuals with isolated brain metastases are candida-
tes for surgical resection. Radiotherapy might be consi-
dered if surgery is not possible (261-263) (B).
Recommendation 12
The currently available treatments for individuals with 
distant metastases of MTC, which include surgery, 
chemotherapy, radiotherapy, and tyrosine-kinase inhi-
bitors, are palliative and might be indicated in selected 
cases to control the disease progression or to improve 
the patient’s quality of life. 
13. When are radioactive iodine treatment and/
or levothyroxine suppressive therapy indicated in 
individuals with MTC?
Unlike differentiated thyroid cancer, which origina-
tes in the follicular cells, MTC originates in the C or 
parafollicular cells; therefore, radioactive iodine treat-
ment and/or levothyroxine suppressive therapy are not 
indicated for MTC management (73) (D). In recent 
studies, the use of radioactive iodine did not show any 
effects relevant to the postoperative management of in-
dividuals with MTC (264) (B). 
Recommendation 13
Neither radioactive iodine treatment (Recommenda-
tion B) nor levothyroxine suppressive therapy is indica-
ted in MTC (Recommendation B).
SUMMARY OF RECOMMENDATIONS
To summarize, the main recommendations for the 
diagnostic assessment, treatment, and follow-up of 
MTC are as follows:
PART I: MTC – DIAgNOSIS
1. A thyroid nodule is the most common clinical 
manifestation of MTC. MTC should be speci-
fically suspected in individuals with family his-
tory of MTC, RET mutations or associations 
with pheochromocytoma, hyperparathyroidism, 
cutaneous lichen amyloidosis, Marfanoid habi-
tus, or mucosal neuromas.
2. FNAB should be included in assessments of 
thyroid nodules suspected of MTC. The diffe-
rential diagnosis might be facilitated by the use 
of additional techniques such as the measure-
ment of calcitonin in the FNAB washout fluid 
and immunocytochemistry.
3. MTC screening via a serum calcitonin measu-
rement in individuals with thyroid nodules re-
mains controversial. Because of problems with 
reference value standardization and its doubtful 
cost-effectiveness, the measurement of serum 
calcitonin is not indicated in the routine inves-
tigation of thyroid nodules. 
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4. The preoperative calcitonin levels correlate with 
the tumor size and the presence of local or dis-
tant metastases. The individuals with suspected 
MTC and calcitonin levels > 150 ng/mL must 
be investigated for the presence of locoregional 
and distant metastases by imaging tests (Flow-
chart 1).
5. Neck US is indicated in all individuals with 
suspected MTC (Recommendation B). In ad-
dition to identifying characteristics suggestive 
of malignancy in the thyroid nodules and al-
lowing the performance of US-guided FNAB, 
US is the most sensitive test for detecting neck 
metastases and thus contributes to therapeutic 
planning. 
6. In individuals with neck metastases and/or cal-
citonin levels > 400 mg/mL, the presence of 
distant metastases should be investigated befo-
re surgery. The presence of pheochromocytoma 
must be investigated by the measurement of 
plasma fractionated metanephrines or urine me-
tanephrine levels, if not available the blood mea-
surement. The presence of hyperparathyroidism 
might be investigated through a serum calcium 
level measurement after adjusting for the albu-
min concentration. 
7. A molecular assessment is indicated for all in-
dividuals with C cell hyperplasia, (familial or 
apparently sporadic) MTC, and/or MEN 2. 
The molecular diagnosis might guide the choi-
ce of therapeutic procedures might guide the 
choice of therapeutic procedures and could 
consequently change the natural course of di-
sease, indicate genetic counseling, and help to 
establish the disease prognosis.
8. All first-degree relatives of individuals with 
MTC and germline RET mutations should be 
subjected to molecular screening.
9. The knowledge of the type of RET mutation 
provides relevant information about the clini-
cal presentation of MEN 2 and the biological 
behaviors of the associated neoplasms 
10. The presence of CLA or Hirschsprung’s disease 
indicates the suspected occurrence of heredi-
tary MTC and therefore the need to perform a 
RET molecular assessment. 
11. In asymptomatic cases or in the absence of 
adrenal masses, urine and/or fractionated plas-
ma metanephrines measurements should begin 
at 8 years of age in individuals with MEN 2B 
or 2A who carry mutations in codons 630 or 
634, and after 20 years of age in the remain-
der of individuals with MEN 2A. Hyperpa-
rathyroidism screening must be performed 
annually by measuring the total calcium and 
albumin levels, starting at 8 years age in car-
riers of mutations in RET codons 630 and 634 
and at 20 years of age in the remainder of indi-
viduals with MEN 2A.
PART II. MTC – SURgICAL TREATMENT
1. The surgical treatment recommended for indi-
viduals with MTC limited to the thyroid gland 
is total thyroidectomy and elective dissection of 
the central compartment. 
2. In cases with locoregional disease, total thyroi-
dectomy with central compartment lymph node 
dissection is indicated (B). Lateral lymph node 
dissection is indicated when metastases are pre-
sent or suspected (B). Less aggressive surgery 
is indicated in cases with advanced local disease 
and/or distant metastases to achieve local di-
sease control while preserving the patient’s voi-
ce, deglutition, and parathyroid function. 
3. In cases with a postoperative MTC diagnosis, 
completion thyroidectomy and prophylactic 
central dissection are indicated. Watchful wai-
ting might apply to selected individuals. 
4. In cases without preoperative hyperparathyroi-
dism, the “in situ” preservation of the para-
thyroid glands is always desirable. When the 
glands are accidentally removed or there is a 
risk of devascularization, the glands should be 
autografted into the sternocleidomastoid mus-
cle. In cases with hyperparathyroidism, MEN 
2A, or prior surgery for MTC, the affected pa-
rathyroid gland should be identified with ima-
ging methods to decide upon a subtotal or total 
parathyroidectomy, followed by a forearm auto-
graft. 
5. The surgical approach in asymptomatic carriers 
RET proto-oncogene mutations should consi-
der the risk stratification according to the affec-
ted codon, as follows: 
 – Group D (MEN 2B): total thyroidectomy 
within the first year of life. In cases with evi-
dence of lymph node metastases, nodule sizes > 
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5 mm, or serum calcitonin levels > 40 pg/mL, 
central compartment dissection is also indica-
ted. Individuals older than 1 year of age are 
indicated for (elective) “prophylactic” central 
dissection.
 – Group C: total thyroidectomy before 5 years 
of age.
 – Groups A and B: total thyroidectomy after 5 
years of age in the absence of evidence of MTC 
(normal serum calcitonin levels and neck US). 
Contrariwise, surgery should be performed be-
fore 5 years of age. 
 Individuals in groups A, B, and C should be sub-
jected to central compartment dissection when 
there is clinical and/or imaging evidence of me-
tastatic disease, the nodule size is ≥ 5 mm, and 
the serum calcitonin level is > 40 pg/mL (D).
6. Individuals with advanced local disease or 
distant metastases should be subjected to less 
aggressive surgeries aimed at achieving local 
disease control while preserving the patient’s 
voice, deglutition, and parathyroid functions, 
as well as avoiding hemorrhagic complica-
tions due to the invasion of vascular structu-
res (D).
7. Elective superior mediastinal dissection is 
usually performed during surgery for MTC. 
The dissection of the lower mediastinum should 
be considered only as a palliative treatment in 
patients with high risk of airway obstruction or 
bleeding.
8. In individuals with pheochromocytoma and 
MTC, adrenalectomy should precede thyroi-
dectomy. Therefore, the presence of pheochro-
mocytoma should be established or ruled out 
before thyroid surgery is performed.
PART III. MTC – FOLLOW-UP
1. Serum calcitonin and CEA levels should be 
measured 2-3 months after surgery. Once the 
calcitonin levels normalize, this measurement 
should be repeated after 6-12 months. Per-
sistently elevated calcitonin/CEA levels are 
suggestive of disease persistence or recurrence 
and indicate the need for further investigation 
to establish the disease extension.
2. The main prognostic factors of survival in in-
dividuals with MTC are age, the tumor stage 
at the time of diagnosis, and the calcitonin and 
CEA doubling times. In individuals with here-
ditary MTC, the main prognostic factor of cure 
and survival is the performance of a prophylac-
tic thyroidectomy following the identification 
of RET gene mutations.
3. Basal calcitonin levels < 150 pg/mL are asso-
ciated with the presence of locoregional disease, 
and neck US should be the first test used in the 
assessment. The likelihood of detecting distant 
metastases is higher among patients with calci-
tonin levels > 150 pg/mL. In such cases, chest 
CT, abdominal MRI, and bone scintigraphy 
should be performed to establish the presence 
of mediastinal and lung, liver, and bone metas-
tases, respectively. 
4. Measurements of serum calcitonin levels should 
be performed every 6-12 months for a still-un-
defined period of time in individuals with un-
detectable levels after surgery due to the risk of 
disease relapse. Measurements of the calcitonin 
level in the FNAB washout fluid might facilitate 
the diagnoses of suspected lesions. 
5. The pentagastrin/calcium stimulation test is 
not indicated for the follow-up of individuals 
with undetectable basal serum calcitonin, as 
positive results denote residual diseases that are 
difficult to locate with imaging methods. 
6. Serum calcitonin is the most relevant biomarker 
for the follow up individuals with MTC. Discre-
te increases in the calcitonin levels (< 150 pg/
mL) usually denote the presence of locoregio-
nal disease. More substantial elevations (> 150 
pg/mL) are suggestive of distant metastases. 
The best methods for investigating metastases 
are US for the neck, CT for the chest, MRI for 
the liver, and bone scintigraphy and/or axial 
skeleton MRI for the bones. 
7. Individuals with elevated serum calcitonin levels 
and negative imaging tests should be assessed 
at least every 6 months, and these assessments 
should include measurements of the calcitonin 
and CEA levels to calculate their DTs. 
8. Systemic treatment should be considered for 
symptomatic individuals and/or those with 
documented significant disease progression (ac-
cording to radiological methods and/or a calci-
tonin or CEA DT < 6 months). 
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9. Advanced MTC metastatic disease might be 
attended by systemic hormonal changes secon-
dary to the increased calcitonin levels and/or 
the ectopic production of some specific hormo-
nes. Treatment should be planned on an indi-
vidual basis according to the clinical manifesta-
tions of the existing dysfunction. 
10. Radiotherapy should be considered for local 
disease control, the palliative treatment of pain-
ful bone metastases or those at risk of fracture, 
and for the treatment of hemoptysis or airway 
obstruction in individuals with extensive me-
diastinal and/or lung involvement. The effects 
of conventional chemotherapy are limited, and 
thus it should only be considered in selected ca-
ses (significant progression of the tumor mass).
11. The results reported to date indicate that tyro-
sine-kinase inhibitors represent a relevant thera-
peutic option for the treatment of locally advan-
ced or metastatic MTC (Recommendation A). 
Nevertheless, the corresponding data regarding 
long-term survival are not yet available. As a 
function of their side effect profiles, caution is 
required when identifying patients who might 
benefit from these drugs (Recommendation D). 
Currently, two tyrosine-kinase inhibitors, van-
detanib and cabozantinib, have been approved 
by the FDA for the treatment of rapidly progres-
sive metastatic MTC, while only the former has 
been approved in Brazil. Advanced metastatic 
MTC might be associated with systemic hormo-
nal changes consequent to increased calcitonin 
levels and/or the ectopic production of specific 
hormones. Treatment should be established on 
an individual basis according to the clinical ma-
nifestations of the existing dysfunction.
12. The currently available treatments for indivi-
duals with distant metastases of MTC, which 
include surgery, chemotherapy, radiotherapy, 
and tyrosine-kinase inhibitors, are palliative and 
might be indicated in selected cases to control 
the disease progression or to improve the pa-
tient’s quality of life. 
13. Neither radioactive iodine treatment nor levo-
thyroxine suppressive therapy is indicated in 
MTC. 
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